<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81923</article-id><article-id pub-id-type="doi">10.7554/eLife.81923</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Beta human papillomavirus 8E6 promotes alternative end joining</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-287703"><name><surname>Hu</surname><given-names>Changkun</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4407-7144</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287704"><name><surname>Bugbee</surname><given-names>Taylor</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287705"><name><surname>Palinski</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287706"><name><surname>Akinyemi</surname><given-names>Ibukun A</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287707"><name><surname>McIntosh</surname><given-names>Michael T</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287708"><name><surname>MacCarthy</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287709"><name><surname>Bhaduri-McIntosh</surname><given-names>Sumita</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-286356"><name><surname>Wallace</surname><given-names>Nicholas</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3971-716X</contrib-id><email>nwallac@ksu.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Basic Sciences Division, Fred Hutchinson Cancer Research Center</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05p1j8758</institution-id><institution>Division of Biology, Kansas State University</institution></institution-wrap><addr-line><named-content content-type="city">Manhattan</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05p1j8758</institution-id><institution>Veterinary Diagnostic Laboratory, Kansas State University</institution></institution-wrap><addr-line><named-content content-type="city">Manhattan</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02y3ad647</institution-id><institution>Child Health Research Institute, Department of Pediatrics, University of Florida</institution></institution-wrap><addr-line><named-content content-type="city">Gainesville</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02y3ad647</institution-id><institution>Department of Molecular Genetics and Microbiology, University of Florida</institution></institution-wrap><addr-line><named-content content-type="city">Gainesville</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05qghxh33</institution-id><institution>Laufer Center for Physical and Quantitative Biology, Stony Brook University</institution></institution-wrap><addr-line><named-content content-type="city">Stony Brook</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Heyer</surname><given-names>Wolf-Dietrich</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05rrcem69</institution-id><institution>University of California, Davis</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Ojala</surname><given-names>Paivi M</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040af2s02</institution-id><institution>University of Helsinki</institution></institution-wrap><country>Finland</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>24</day><month>01</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e81923</elocation-id><history><date date-type="received" iso-8601-date="2022-07-16"><day>16</day><month>07</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-01-23"><day>23</day><month>01</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-07-30"><day>30</day><month>07</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.07.29.501983"/></event></pub-history><permissions><copyright-statement>Â© 2023, Hu et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Hu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81923-v3.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-81923-figures-v3.pdf"/><abstract><p>Double strand breaks (DSBs) are one of the most lethal DNA lesions in cells. The E6 protein of beta-human papillomavirus (HPV8 E6) impairs two critical DSB repair pathways: homologous recombination (HR) and non-homologous end joining (NHEJ). However, HPV8 E6 only delays DSB repair. How DSBs are repaired in cells with HPV8 E6 remains to be studied. We hypothesize that HPV8 E6 promotes a less commonly used DSB repair pathway, alternative end joining (Alt-EJ). Using CAS9-based Alt-EJ reporters, we show that HPV8 E6 promotes Alt-EJ. Further, using small molecule inhibitors, CRISPR/CAS9 gene knockout, and HPV8 E6 mutant, we find that HPV8 E6 promotes Alt-EJ by binding p300, an acetyltransferase that facilitates DSB repair by HR and NHEJ. At least some of this repair occurs through a subset of Alt-EJ known as polymerase theta dependent end joining. Finally, whole genome sequencing analysis showed HPV8 E6 caused an increased frequency of deletions bearing the microhomology signatures of Alt-EJ. This study fills the knowledge gap of how DSB is repaired in cells with HPV8 E6 and the mutagenic consequences of HPV8 E6 mediated p300 destabilization. Broadly, this study supports the hypothesis that beta-HPV promotes cancer formation by increasing genomic instability.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>beta-HPV</kwd><kwd>DSB repair</kwd><kwd>MMEJ</kwd><kwd>P300</kwd><kwd>NHEJ</kwd><kwd>HR</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>P20GM130448</award-id><principal-award-recipient><name><surname>Wallace</surname><given-names>Nicholas</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>NCI R15 CA242057 01A1</award-id><principal-award-recipient><name><surname>Wallace</surname><given-names>Nicholas</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id><institution>U.S. Department of Defense</institution></institution-wrap></funding-source><award-id>CMDRP PRCRP CA160224 (NW)</award-id><principal-award-recipient><name><surname>Wallace</surname><given-names>Nicholas</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Human papillomavirus type 8 E6 promotes alternative end joining by compromising non-homologous end joining and homologous recombination.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Beta genus human papillomaviruses (beta-HPVs) are ubiquitous and transiently infect cutaneous epithelia in the general population (<xref ref-type="bibr" rid="bib6">Bouwes Bavinck et al., 2018</xref>; <xref ref-type="bibr" rid="bib16">Gheit, 2019</xref>; <xref ref-type="bibr" rid="bib37">Neale et al., 2013</xref>). Beta-HPVs, including type 8 (HPV8), are associated with nonmelanoma skin cancer (NMSC) in immunocompromised individuals including people with a rare genetic disorder epidermodysplasia verruciformis and organ transplant recipients (<xref ref-type="bibr" rid="bib6">Bouwes Bavinck et al., 2018</xref>; <xref ref-type="bibr" rid="bib5">Bouwes Bavinck et al., 2001</xref>; <xref ref-type="bibr" rid="bib11">DellâOste et al., 2009</xref>; <xref ref-type="bibr" rid="bib47">Sichero et al., 2019</xref>). However, the contribution of beta-HPV infections to NMSC in the general population is unclear. Because beta-HPV infections are not persistent in immunocompetent people, they are hypothesized to promote cancer formation by making UV-induced DNA damage more mutagenic (<xref ref-type="bibr" rid="bib23">Hufbauer et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Spriggs and Laimins, 2017</xref>; <xref ref-type="bibr" rid="bib61">Wendel and Wallace, 2017</xref>). In support of this hypothesis, our group and others have used in vitro and in vivo systems to demonstrate that the E6 protein from HPV8 (8E6) impairs DNA repair (<xref ref-type="bibr" rid="bib23">Hufbauer et al., 2015</xref>; <xref ref-type="bibr" rid="bib45">Rollison et al., 2019</xref>; <xref ref-type="bibr" rid="bib56">Wallace et al., 2012</xref>).</p><p>The interaction with and destabilization of p300 is a key mechanism by which 8E6 hinders DNA repair (<xref ref-type="bibr" rid="bib9">Dacus and Wallace, 2021</xref>; <xref ref-type="bibr" rid="bib18">Howie et al., 2011</xref>). P300 is an acetyltransferase that regulates transcription by chromatin remodeling (<xref ref-type="bibr" rid="bib1">Ait-Si-Ali et al., 2000</xref>; <xref ref-type="bibr" rid="bib14">Dutto et al., 2018</xref>; <xref ref-type="bibr" rid="bib17">Goodman and Smolik, 2000</xref>). By binding p300, 8E6 decreases the abundance of multiple DNA repair proteins including ATR, ATM, BRCA1, and BRCA2 (<xref ref-type="bibr" rid="bib58">Wallace et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Wallace et al., 2013</xref>; <xref ref-type="bibr" rid="bib56">Wallace et al., 2012</xref>). This lowers the activation of ATM and ATR signaling, decreasing the cellular response to UV-damaged DNA (<xref ref-type="bibr" rid="bib49">Snow et al., 2019</xref>; <xref ref-type="bibr" rid="bib56">Wallace et al., 2012</xref>). The limited ability to repair UV damage increases the frequency with which UV causes replication forks to collapse into double strand breaks (DSBs) in DNA (<xref ref-type="bibr" rid="bib39">Pathania et al., 2011</xref>; <xref ref-type="bibr" rid="bib43">Rapp and Greulich, 2004</xref>). Cells have multiple DSB repair mechanisms. Homologous recombination (HR) is minimally mutagenic, but restricted to in S/G2 phase when the sister chromatids can serve as homologous templates (<xref ref-type="bibr" rid="bib38">Orthwein et al., 2015</xref>; <xref ref-type="bibr" rid="bib46">Shibata et al., 2011</xref>). Whenever possible cells use HR to fix DSBs as it allows them to avoid mutations. When HR is inhibited (by cell cycle position, mutation to repair factors, or artificially), non-homologous end joining (NHEJ) is used to repair DSBs (<xref ref-type="bibr" rid="bib60">Wang et al., 2018</xref>). NHEJ can occur throughout the cell cycle, as it does not require a homologous template. However, because NHEJ generates and ligates blunt ends to fix a DSB, it is more mutagenic than HR (<xref ref-type="bibr" rid="bib34">Mao et al., 2008</xref>). We have shown that 8E6 attenuates both HR and NHEJ by degrading p300 (<xref ref-type="bibr" rid="bib19">Hu et al., 2020</xref>; <xref ref-type="bibr" rid="bib22">Hu and Wallace, 2022c</xref>; <xref ref-type="bibr" rid="bib58">Wallace et al., 2015</xref>).</p><p>Notably, 8E6 does not block the initiation of NHEJ or HR. NHEJ initiation occurs when DNA-dependent protein kinase catalytic subunit (DNA-PKcs) complexes at DSBs and activates itself by autophosphorylation (pDNA-PKcs) (<xref ref-type="bibr" rid="bib10">Davis et al., 2014</xref>; <xref ref-type="bibr" rid="bib25">Jiang et al., 2015</xref>). This occurs readily in the presence of 8E6. However, 8E6 prevents the resolution of pDNA-PKcs repair complexes and attenuates other downstream steps in NHEJ (<xref ref-type="bibr" rid="bib19">Hu et al., 2020</xref>). Similarly, 8E6 allows the HR pathway to initiate, before hindering the resolution of RAD51 repair complexes (<xref ref-type="bibr" rid="bib58">Wallace et al., 2015</xref>). We recently demonstrated that cells respond to 8E6-associated inhibition of NHEJ by trying to complete HR during G1 (<xref ref-type="bibr" rid="bib20">Hu et al., 2022a</xref>; <xref ref-type="bibr" rid="bib21">Hu et al., 2022b</xref>). This ultimately leads to persistent unresolved RAD51 repair complexes formed during G1.</p><p>Thus, currently there is a detailed understanding of how 8E6 causes DSB repair to fail, but less is known about how DSB repair occurs in cells that express 8E6. When NHEJ and HR fail, another mutagenic repair pathway known as alternative end joining (Alt-EJ) is tasked with completing DSB repair (<xref ref-type="bibr" rid="bib24">Iliakis et al., 2015</xref>). Here, we use reporter constructs and small molecule inhibitors of DNA repair factors to demonstrate that 8E6 promotes DSB repair by Alt-EJ and to show that the use of Alt-EJ is the indirect result of initiating NHEJ when the pathway cannot be completed. We also employ whole genome sequence analysis of cells expressing 8E6 and passage matched empty vector control expressing cells to determine the frequency with which 8E6 promotes mutations with the characteristics of repair by Alt-EJ. These observations address a key knowledge gap in the field. By promoting DSB repair by Alt-EJ, 8E6 increases the risk of mutations associated with DSBs while allowing cells to avoid the apoptosis that would be associated with an unrepaired DSB. This is consistent with the proposed mechanism by which beta-HPV infections are hypothesized to promote NMSC.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>8E6 promotes DSB repair by Alt-EJ</title><p>8E6 delays rather than abrogates DSB repair, but it is unclear how these lesions are repaired as 8E6 hinders the completion of HR and NHEJ. Because Alt-EJ serves as another DSB repair mechanism should HR and NHEJ fail, we hypothesized that DSBs were instead repaired by Alt-EJ. To test this, we examined previously described telomerase (N/TERT) immortalized human foreskin keratinocyte (HFK) expressing vector control (HFK LXSN) and 8E6 (HFK 8E6) (<xref ref-type="bibr" rid="bib3">Bedard et al., 2008</xref>). An established reporter cassette where a 46 nt insertion disrupts a GFP open reading frame was used to measure Alt-EJ (<xref ref-type="bibr" rid="bib4">Bhargava et al., 2018</xref>; <xref ref-type="bibr" rid="bib53">Tsai et al., 2020</xref>). <xref ref-type="fig" rid="fig1">Figure 1A</xref> describes Alt-EJ that requires resection (imbedded) and Alt-EJ that occurs independent of resection (terminal). The end joining is mediated by a 4 nt microhomology (ACGG). Transient transfection of this reporter into HFK LXSN and HFK 8E6 demonstrated that 8E6 increased terminal and imbedded Alt-EJ (<xref ref-type="fig" rid="fig1">Figure 1BâE</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>). Transfection efficiency varies between independent experiments, but no significant difference was observed among groups within each experiment (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>8E6 promotes alternative end joining (Alt-EJ) frequency.</title><p>(<bold>A</bold>) Schematic of Alt-EJ reporter. GFP is disrupted by a 46 nt insertion. One CAS9 is used to induce an upstream double strand break (DSB) (5â end) and another CAS9 is used to induce a downstream DSB (either imbedded or terminal). Following CAS9 expression, a 4 nt microhomology (ACGG) mediated Alt-EJ event can restore GFP expression. (<bold>B</bold>) Representative images of flow cytometry results of HFK cells that are GFP positive 24 hr after transfection with terminal Alt-EJ. The gating represents GFP positive based off mock transfected control. The x-axis shows cells distributed by forward scatter to avoid debris. (<bold>C</bold>) Percentage of HFK cells that are positive for GFP following transfection with terminal Alt-EJ determined by flow cytometry. (<bold>D</bold>) Representative images of flow cytometry results of HFK cells that are GFP positive 24 hr after transfection with imbedded Alt-EJ. The gating represents GFP positive based off mock transfected control. The x-axis shows cells distributed by forward scatter to avoid debris. (<bold>E</bold>) Percentage of HFK cells that are positive for GFP following transfection with imbedded Alt-EJ determined by flow cytometry. All values are represented as mean Â± standard error. The statistical significance of differences between cell lines were determined using Studentâs t-test. p-Values indicate significant difference between cell lines. Twenty thousand cells were counted for each of three independent flow cytometry experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81923-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 1.</label><caption><title>Transfection efficiency represented by CAS9 expression in hTERT human foreskin keratinocyte (HFK).</title><p>(<bold>A</bold>) Representative immunoblotting of CAS9 after transfection with terminal alternative end joining (Alt-EJ). GAPDH is used as a loading control. (<bold>B</bold>) Densitometry of CAS9 level in cells transfected with terminal Alt-EJ. (<bold>C</bold>) Representative immunoblotting of CAS9 after transfection with imbedded Alt-EJ. GAPDH is used as a loading control. (<bold>D</bold>) Densitometry of CAS9 level in cells transfected with imbedded Alt-EJ. All values are represented as mean Â± standard error (n=3). The statistical significance of differences between cell lines were determined using Studentâs t-test. No significant differences were obtained.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1âfigure supplement 1âsource data 1.</label><caption><title>Original blots with and without labels in <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81923-fig1-figsupp1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81923-fig1-figsupp1-v3.tif"/></fig></fig-group><p>To further confirm that 8E6 promoted Alt-EJ, we examined DSB repair in cells where Alt-EJ was blocked by a small molecule inhibitor against PARP-1, an established component of the Alt-EJ pathway (1 ÂµM of olaparib) (<xref ref-type="bibr" rid="bib27">KÃ¶tter et al., 2014</xref>). We confirmed that PARP-1 inhibition blocked Alt-EJ using the reporter system described above (<xref ref-type="fig" rid="fig2">Figure 2AâD</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>). DSBs were induced by growth in media containing zeocin (10 Âµg/mL, 10 min), a radiation mimetic reagent (<xref ref-type="bibr" rid="bib54">Tsukuda and Miyazaki, 2013</xref>). H2AX phosphorylated at Serine 139 or pH2AX is used as a standard DSB marker (<xref ref-type="bibr" rid="bib44">Rogakou et al., 1998</xref>). PARP-1 inhibition did not significantly alter DSB repair in HFK LXSN cells (<xref ref-type="fig" rid="fig2">Figure 2EâF</xref>). This is consistent with the established view that most DSB repair occurs via either HR or NHEJ, with Alt-EJ serving as a fail-safe machinery should these pathways fail (<xref ref-type="bibr" rid="bib24">Iliakis et al., 2015</xref>; <xref ref-type="bibr" rid="bib40">Patterson-Fortin and DâAndrea, 2020</xref>; <xref ref-type="bibr" rid="bib48">Simsek and Jasin, 2010</xref>). In contrast, PARP-1 inhibition significantly delayed DSB repair in HFK 8E6 cells (<xref ref-type="fig" rid="fig2">Figure 2EâF</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Olaparib abrogates alternative end joining (Alt-EJ) frequency and increases persistent pH2AX.</title><p>(<bold>A</bold>) Representative images of flow cytometry results of human foreskin keratinocyte (HFK) cells treated with DMSO or olaparib (1 Î¼M) that are GFP positive 24 hr after transfection with terminal Alt-EJ. The gating represents GFP positive based off mock transfected control. The x-axis shows cells distributed by forward scatter to avoid debris. (<bold>B</bold>) Percentage of HFK cells that are positive for GFP following transfection with terminal Alt-EJ determined by flow cytometry. (<bold>C</bold>) Representative images of flow cytometry results of HFK cells treated with DMSO or olaparib that are GFP positive 24 hr after transfection with imbedded Alt-EJ. The gating represents GFP positive based off mock transfected control. The x-axis shows cells distributed by forward scatter to avoid debris. (<bold>D</bold>) Percentage of HFK cells that are positive for GFP following transfection with imbedded Alt-EJ determined by flow cytometry. (<bold>E</bold>) Representative images of pH2AX in HFK LXSN and HFK 8E6 treated with DMSO or olaparib (1 Î¼M) following zeocin treatment (10 Î¼g/mL, 10 min). (<bold>F</bold>) Percentage of pH2AX foci positive cells in HFK LXSN and HFK 8E6 treated with DMSO or olaparib following zeocin treatment. All values are represented as mean Â± standard error. The statistical significance of differences between treatments were determined using Studentâs t-test. p-Values indicate significant difference between DMSO and olaparib with same cell line (p&lt;0.05). Twenty thousand cells were counted for each of three independent flow cytometry experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81923-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 1.</label><caption><title>Transfection efficiency represented by CAS9 expression in hTERT human foreskin keratinocyte (HFK).</title><p>(<bold>A</bold>) Representative immunoblotting of CAS9 in cells treated with DMSO or olaparib (1 Î¼M) after transfection with terminal alternative end joining (Alt-EJ). GAPDH is used as a loading control. (<bold>B</bold>) Densitometry of CAS9 level in cells tranfected with terminal Alt-EJ. (<bold>C</bold>) Representative immunoblotting of CAS9 in cells treated with DMSO or olaparib after transfection with imbedded Alt-EJ. (<bold>D</bold>). Densitometry of CAS9 level in cells tranfected with imbedded Alt-EJ. All values are represented as mean Â± standard error (n=3). The statistical significance of differences between cell lines were determined using Studentâs t-test. No significant differences were obtained.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2âfigure supplement 1âsource data 1.</label><caption><title>Original blots with and without labels in <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81923-fig2-figsupp1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81923-fig2-figsupp1-v3.tif"/></fig></fig-group><p>Alt-EJ is an umbrella term that includes any end joining event that does not require DNA-PKcs activity. While most Alt-EJ relies on PARP-1, a subset of Alt-EJ can occur when PARP-1 activity is impaired. Specifically, loss of PARP-1 activity only reduces polymerase theta mediated end joining (TMEJ) by two- to fourfold (<xref ref-type="bibr" rid="bib33">Luedeman et al., 2022</xref>). To begin determining the extent that 8E6 promoted TMEJ, we used immunoblots to determine if 8E6 increased the abundance of polymerase theta (POLÎ¸). This analysis did not find any notable changes in POLÎ¸ abundance (<xref ref-type="fig" rid="fig3">Figure 3AâB</xref>). We next used a small molecule inhibitor of POLÎ¸ (ART558) to determine if HFK 8E6 cells were reliant on POLÎ¸ activity, using an MTT assay to detect viability. There were no significant differences in viability between HFK LXSN and HFK 8E6 cells when grown in media containing a gradient (0â50 Î¼M) of ART558 concentrations (<xref ref-type="fig" rid="fig3">Figure 3C</xref>) However, 8E6 impairs apoptosis by degrading BAK, which complicates the interpretation of these data. To more directly define the extent that 8E6 promotes DSB repair by TMEJ, we determined the extent that POLÎ¸ inhibition impaired DSB repair. For this analysis, we induced DSBs by growth media containing zeocin (10 Âµg/mL, 10 min). Cells were then switched to media containing DMSO (solvent control), 1 Î¼M 558, or 5 Î¼M ART 558. DSBs were detected by immunofluorescence microscopy of pH2AX24 hr later. These concentrations of ART558 were analyzed because they caused the largest differences in viability between HFK 8E6 and HFK LXSN cells. ART558 delayed DSB repair in HFK 8E6 cells but not in HFK LXSN cells, indicating that 8E6 promoted repair by TMEJ (<xref ref-type="fig" rid="fig3">Figure 3DâE</xref>). However, although statistically significant, the increased persistence of pH2AX foci was a much lower magnitude than what PARP1 inhibition caused. These experiments were also repeated with higher concentrations of ART558, but no differences in the persistence of pH2AX was detected (not shown). We interpret these data as evidence that 8E6 inhibits multiple types of DNA-PKcs-independent end joining, including but not limited to TMEJ. For simplicity, we will only use the term Alt-EJ moving forward.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>8E6 promotes polymerase theta (POLÎ¸)-dependent double strand break (DSB) repair.</title><p>(<bold>A</bold>) Representative immunoblotting of POLÎ¸ in human foreskin keratinocyte (HFK) LXSN and HFK 8E6 cells. (<bold>B</bold>) Densitometry of POLÎ¸ level in HFK LXSN and HFK 8E6 cells. (<bold>C</bold>) Relative cell viability at various ART558 concentrations in HFK LXSN and HFK 8E6 following zeocin treatment. (<bold>D</bold>) Representative images of pH2AX in HFK LXSN and HFK 8E6 treated with DMSO or ART588 (1 or 5 Î¼M) 24 hr following zeocin treatment (10 Î¼g/mL, 10 min). (<bold>E</bold>) Average number of pH2AX foci per cell in HFK LXSN and HFK 8E6 treated with DMSO or ART558 following zeocin treatment. The statistical significance of differences between treatments were determined using Studentâs t-test. p-Values indicate significant difference between HFK LXSN and HFK 8E6 with same ART588 treatment (p&lt;0.05). At least 40 cells were counted for each of three independent microscopy experiments.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3âsource data 1.</label><caption><title>Original blots with and without labels in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81923-fig3-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81923-fig3-v3.tif"/></fig></sec><sec id="s2-2"><title>DNA-PK inhibition forces 8E6 expressing cells to use Alt-EJ more frequently</title><p>NHEJ initiation blocks DSB repair by other pathways, including Alt-EJ (<xref ref-type="bibr" rid="bib40">Patterson-Fortin and DâAndrea, 2020</xref>; <xref ref-type="bibr" rid="bib48">Simsek and Jasin, 2010</xref>; <xref ref-type="bibr" rid="bib59">Wang et al., 2006</xref>). 8E6 does not prevent the initiation of NHEJ as autophosphorylated DNA-PKcs foci form readily in HFK 8E6 cells (<xref ref-type="bibr" rid="bib19">Hu et al., 2020</xref>). Instead, 8E6 blocks the completion of NHEJ. Thus, we hypothesized that preventing HFK 8E6 cells from initiating NHEJ would force them to repair DSBs via Alt-EJ. To test this, we determined the frequency of Alt-EJ in HFK LXSN and HFK 8E6 cells in the presence of a small molecule inhibitor of DNA-PKcs (1 ÂµM of NU7441) to block NHEJ initiation. As expected, DNA-PKcs inhibition increased both imbedded and terminal Alt-EJ in HFK LXSN cells (<xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>). However, the increase in HFK LXSN cells did not reach the levels of Alt-EJ in mock-treated HFK 8E6 cells. DNA-PKcs inhibition resulted in a further significant increased use of Alt-EJ in HFK 8E6 cells. Together these data support the conclusion that 8E6 promotes the use of Alt-EJ and that the use of the pathway is further enhanced if cells are not allowed to initiate NHEJ.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>NU7441 promotes alternative end joining (Alt-EJ).</title><p>(<bold>A</bold>) Representative images of flow cytometry results of human foreskin keratinocyte (HFK) cells treated with DMSO or NU7441 (1 Î¼M) that are GFP positive 24 hr after transfection with terminal Alt-EJ. The gating represents GFP positive based off mock transfected control. The x-axis shows cells distributed by forward scatter to avoid debris. (<bold>B</bold>) Percentage of HFK cells that are positive for GFP following transfection with terminal Alt-EJ determined by flow cytometry. (<bold>C</bold>) Representative images of flow cytometry results of HFK cells treated with DMSO or NU7441 that are GFP positive 24 hr after transfection with imbedded Alt-EJ. The gating represents GFP positive based off mock transfected control. The x-axis shows cells distributed by forward scatter to avoid debris. (<bold>D</bold>) Percentage of HFK cells that are positive for GFP following transfection with imbedded Alt-EJ determined by flow cytometry. All values are represented as mean Â± standard error. The statistical significance of differences between treatments were determined using Studentâs t-test. p-Values indicate significant difference between DMSO and NU7441 within the same cell line. Twenty thousand cells were counted for each of three independent flow cytometry experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81923-fig4-v3.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 1.</label><caption><title>Transfection efficiency represented by CAS9 expression in hTERT human foreskin keratinocyte (HFK).</title><p>(<bold>A</bold>) Representative immunoblotting of CAS9 in cells treated with DMSO or NU7441 (1 Î¼M) after transfection with terminal alternative end joining (Alt-EJ). GAPDH is used as a loading control. (<bold>B</bold>) Densitometry of CAS9 level in cells tranfected with terminal Alt-EJ. (<bold>C</bold>) Representative immunoblotting of CAS9 in cells treated with DMSO or NU7441 after transfection with imbedded Alt-EJ. GAPDH is used as a loading control. (<bold>D</bold>) Densitometry of CAS9 level in cells tranfected with imbedded Alt-EJ. All values are represented as mean Â± standard error (n=3). The statistical significance of differences between cell lines were determined using Studentâs t-test. No significant differences were obtained.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4âfigure supplement 1âsource data 1.</label><caption><title>Original blots with and without labels in <xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81923-fig4-figsupp1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81923-fig4-figsupp1-v3.tif"/></fig></fig-group><p>When HFK 8E6 cells are allowed to initiate NHEJ, many of the pDNA-PKcs repair complexes that form persist for over 24 hr (<xref ref-type="bibr" rid="bib19">Hu et al., 2020</xref>). HR factors (e.g., RAD51) are then recruited to these unresolved repair foci (<xref ref-type="bibr" rid="bib20">Hu et al., 2022a</xref>). However, HR is ultimately unable to repair the lesions. We hypothesized that forcing HFK 8E6 cells to use Alt-EJ by preventing initiation of NHEJ would lead to more efficient DSB repair by allowing them to avoid these abortive attempts at DSB repair. NU7441 (1 mM) was used to block NHEJ initiation and DSBs were detected using pH2AX. As we have shown before, DSBs were more persistent in mock-treated 8E6 cells than LXSN cells. Supporting our hypothesis, DNA-PKcs inhibition made DSB repair more efficient (less pH2AX) in HFK 8E6 cells (<xref ref-type="fig" rid="fig5">Figure 5AâB</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Nu7441 increases double strand break (DSB) repair in cells with 8E6.</title><p>(<bold>A</bold>) Representative images of pH2AX in human foreskin keratinocyte (HFK) LXSN and HFK 8E6 treated with NU7441 (1 Î¼M) following zeocin treatment (10 Î¼g/mL, 10 min). (<bold>B</bold>) Percentage of pH2AX foci positive cells in HFK LXSN and HFK 8E6 treated with NU7441 following zeocin treatment. (<bold>C</bold>) Representative images of RAD51 in HFK LXSN and HFK 8E6 treated with NU7441 following zeocin treatment. (<bold>D</bold>) Percentage of RAD51 foci positive cells in HFK LXSN and HFK 8E6 treated with NU7441 following zeocin treatment. (<bold>E</bold>) Representative images of pH2AX in HFK LXSN and HFK 8E6 treated with SCR7 (1 Î¼M) following zeocin treatment. (<bold>F</bold>) Percentage of pH2AX foci positive cells in HFK LXSN and HFK 8E6 treated with SCR7 following zeocin treatment. All values are represented as mean Â± standard error. The statistical significance of differences between treatments were determined using Studentâs t-test. p-Values indicate significant difference between DMSO and inhibitor treated with the same cell line. At least 150 cells were counted over three independent experiments. Nuclei were determined by DAPI staining. The edge of this staining is shown by a white line depicting the nucleus.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81923-fig5-v3.tif"/></fig><p>We next determined the extent that DNA-PKcs inhibition in HFK 8E6 cells resulted in increased resolution of RAD51 foci. As we have previously reported (<xref ref-type="bibr" rid="bib20">Hu et al., 2022a</xref>), DNA-PKcs inhibition increased the persistence of RAD51 in HFK LXSN (<xref ref-type="fig" rid="fig5">Figure 5CâD</xref>). A similar increase in RAD51 persistence was also seen in mock-treated HFK 8E6 cells. However, DNA-PKcs inhibition increased the rate of RAD51 resolution in HFK 8E6 (<xref ref-type="fig" rid="fig5">Figure 5CâD</xref>). To determine if inhibition of a later step in the NHEJ pathway also increased the efficiency of DSB repair in HFK 8E6 cells, we used a small molecule inhibitor of ligase IV (1 ÂµM of SCR7) to block a near terminal step in NHEJ. Ligase IV inhibition delayed DSB repair in both HFK LXSN and HFK 8E6 cells (<xref ref-type="fig" rid="fig5">Figure 5EâF</xref>). Thus, restoration of DSB repair in HFK 8E6 specifically requires inhibition of an early NHEJ step, rather than inhibition of a later step in the pathway.</p></sec><sec id="s2-3"><title>DNA-PKcs inhibition prevents 8E6 from causing RAD51 foci to form during G1</title><p>The persistent RAD51 repair complexes that form in HFK 8E6 cells occur during G1 (<xref ref-type="bibr" rid="bib20">Hu et al., 2022a</xref>). These observations and the ones described in <xref ref-type="fig" rid="fig4">Figure 4</xref> led us to hypothesize that blocking NHEJ initiation via DNA-PKcs inhibition would prevent 8E6 from causing RAD51 foci to form in G1. To test this, we detected RAD51 foci and cyclin E (G1 marker) after the induction of DSB by zeocin. DNA-PKcs inhibition increased the frequency of HFK LXSN in G1 that contained RAD51 foci (<xref ref-type="fig" rid="fig6">Figure 6AâB</xref>). Without DNA-PKcs inhibition, 8E6 increased the frequency of cells in G1 that had RAD51 foci. However, DNA-PKcs inhibition prevented 8E6 from promoting the formation of RAD51 repair complexes during G1. As cyclin E is also expressed during early S phase, this examination was repeated using cyclin A as a marker of cells in S/G2 (<xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1</xref>). These experiments confirmed our observations using cyclin E to determine cell cycle position, providing further evidence that DNA-PKcs inhibition prevented 8E6 from promoting the formation of RAD51 foci during G1 (<xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1</xref>). We used flow cytometry as a final determinant of cell cycle position, using NUCLEAR-ID Red DNA staining to select cells in G1 based on DNA content and then determined the frequency with which these cells stained for RAD51 (<xref ref-type="fig" rid="fig6s2">Figure 6âfigure supplement 2</xref>). Consistent with our hypothesis, DNA-PKcs inhibition increased the frequency of RAD51 in G1 in HFK LXSN and prevented 8E6 from promoting RAD51 in G1 (<xref ref-type="fig" rid="fig6">Figure 6CâD</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>NU7441 abrogates RAD51 in G1 induced by 8E6.</title><p>(<bold>A</bold>) Representative cyclin E negative and positive human foreskin keratinocyte (HFK) LXSN and HFK 8E6 cells stained for RAD51 (green) and cyclin E (red) treated with DMSO or NU7441 (1 Î¼M) 24 hr following zeocin treatment (10 Âµg/mL, 10 min). (<bold>B</bold>) Percentage of RAD51 positive HFK cell in G1 determined by cyclin E staining after zeocin treatment. (<bold>C</bold>) Representative images of flow cytometry results of HFK LXSN and HFK 8E6 cells in G1 stained with RAD51 treated with DMSO or NU7441 24 hr after zeocin treatment. RAD51 intensity is determined by Alexa 488-conjugated secondary antibody and shown on the y-axis. The gating represents RAD51 positive based off secondary only control. The x-axis shows cells distributed by forward scatter to avoid debris. (<bold>D</bold>) Percentage of HFK cells in G1 that are positive for RAD51 as determined by flow cytometry. Nuclei were determined by DAPI staining. The edge of this staining is shown by a white line depicting the nucleus. All values are represented as mean Â± standard error. The statistical significance of differences between treatments were determined using Studentâs t-test. p-Values indicate significant difference between DMSO and NU7441 treatment with the same cell line. At least 150 cells were counted over three independent experiments for microscopy. Twenty thousand cells were counted for each of three independent flow cytometry experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81923-fig6-v3.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6âfigure supplement 1.</label><caption><title>NU7441 abrogates RAD51 in G1 (cyclin A negative) induced by 8E6.</title><p>Percentage of RAD51 positive human foreskin keratinocyte (HFK) cell treated by DMSO or NU7441 (1 Î¼M) in G1 determined by cyclin A negative after zeocin treatment (10 Î¼g/mL, 10 min). All values are represented as mean Â± standard error. The statistical significance of differences between treatments were determined using Studentâs t-test. p-Values indicate significant difference between DMSO and NU7441 treatment with same cell line. At least 150 cells were counted over three independent experiments for microscopy.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81923-fig6-figsupp1-v3.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6âfigure supplement 2.</label><caption><title>Controls were used to determine RAD51 staining cutoff and G1 gating in human foreskin keratinocyte (HFK) cells by flow cytometry.</title><p>(<bold>A</bold>) Representative images of cell cycle analysis by flow cytometry following zeocin treatment (10 Âµg/mL, 10 min). NUCLEAR-ID Red DNA stain was used to determine DNA content and G1 (blue). (<bold>B</bold>) Representative images of flow cytometry results of HFK LXSN and HFK 8E6 cells stained with Alexa 488-conjugated secondary antibody and shown on the y-axis. The gating represents RAD51 positive based off secondary only control. The x-axis shows cells distributed by forward scatter to avoid debris. Twenty thousand cells were counted for each of three flow cytometry experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81923-fig6-figsupp2-v3.tif"/></fig></fig-group></sec><sec id="s2-4"><title>DNA-PKcs inhibition does not promote HR in cells with 8E6</title><p>The data above demonstrate that the attenuation of DSB repair by 8E6 can be overcome by inhibiting DNA-PKcs. DNA-PKcs inhibition also increases the resolution of RAD51, suggesting that DNA-PKcs inhibition may prevent 8E6 from attenuating HR. To test this, we measured HR efficiency using an established HR reporter, described in <xref ref-type="fig" rid="fig7">Figure 7A</xref> (<xref ref-type="bibr" rid="bib42">Pierce et al., 1999</xref>). In vector control U2OS cells (U2OS LXSN), NU7441 increases HR efficiency (<xref ref-type="fig" rid="fig7">Figure 7BâC</xref>). This is consistent with the established idea that NHEJ and HR compete for access to DSBs (<xref ref-type="bibr" rid="bib7">Bunting et al., 2010</xref>; <xref ref-type="bibr" rid="bib8">Chapman et al., 2012</xref>; <xref ref-type="bibr" rid="bib38">Orthwein et al., 2015</xref>). As previously reported, 8E6 in U2OS cells (U2OS 8E6) decreased HR efficiency (<xref ref-type="bibr" rid="bib58">Wallace et al., 2015</xref>). However, DNA-PKcs inhibition did not prevent 8E6 from hindering HR (<xref ref-type="fig" rid="fig7">Figure 7BâC</xref>). Consistent with a p300-dependent mechanism (see next section for more details), U2OS cells expressing 8E6 with the residues responsible for binding p300 deleted (U2OS 8E6Î132â136) were similar to vector control (<xref ref-type="fig" rid="fig7">Figure 7BâC</xref>). These cell lines have been previously described (<xref ref-type="bibr" rid="bib19">Hu et al., 2020</xref>; <xref ref-type="bibr" rid="bib58">Wallace et al., 2015</xref>). U2OS cells are routinely used to probe 8E6 biology because 8E6 retains its ability to alter DNA repair in these cells (<xref ref-type="bibr" rid="bib19">Hu et al., 2020</xref>; <xref ref-type="bibr" rid="bib58">Wallace et al., 2015</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>NU7441 does not increase homologous recombination (HR) in cells with 8E6.</title><p>(<bold>A</bold>) Schematic of DR-GFP reporter. GFP open reading frame is disrupted by insertion of ISCE-1 site (SceGFP). Downstream of the reporter is a truncated internal GFP(iGFP) that can be used as a template to remove the ISCE-1 site and restore GFP expression during HR event. (<bold>B</bold>) Representative images of flow cytometry results of U2OS cells that are GFP positive treated with DMSO or NU7441(1 Î¼M) 24 hr after ISCE-1 transfection. The gating represents GFP positive based off mock transfected control. The x-axis shows cells distributed by forward scatter to avoid debris. (<bold>C</bold>) Percentage of U2OS cells that are positive for GFP determined by flow cytometry. All values are represented as mean Â± standard error. The statistical significance of differences between treatments were determined using Studentâs t-test. p-Values indicate significant difference between DMSO and NU7441 with same cell line. Twenty thousand cells were counted for each of three independent flow cytometry experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81923-fig7-v3.tif"/></fig></sec><sec id="s2-5"><title>8E6 promotes Alt-EJ by destabilizing p300</title><p>8E6 delays DSB repair by binding/destabilizing p300, leading us to hypothesize that the residues of 8E6 that facilitate the interaction with p300 were important for the phenotypes described thus far (<xref ref-type="bibr" rid="bib20">Hu et al., 2022a</xref>, <xref ref-type="bibr" rid="bib19">Hu et al., 2020</xref>; <xref ref-type="bibr" rid="bib58">Wallace et al., 2015</xref>). To test this, we examined U2OS LXSN, U2OS 8E6, and U2OS 8E6Î132â136 cells. Consistent with the p300-dependent mechanism, 8E6Î132â136 shows similar Alt-EJ frequency with U2OS LXSN (<xref ref-type="fig" rid="fig7">Figure 7AâB</xref>). The deletion of these residues from 8E6 has been shown to prevent some but not all aspects of 8E6 biology. As a result, we examined p300 knockout N/TERT immortalized HFK cells. P300 knockout led to increases in both terminal and imbedded Alt-EJ (<xref ref-type="fig" rid="fig8">Figure 8CâD</xref>). To further confirm p300 dependence, we used a small molecule inhibitor of p300 (1 ÂµM of CCS1477) to block p300 activity. Consistently, CCS1477 increased both terminal and imbedded Alt-EJ (<xref ref-type="fig" rid="fig8">Figure 8EâF</xref>).</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Losing p300 activity promotes alternative end joining (Alt-EJ) frequency.</title><p>(<bold>AâB</bold>) Percentage of U2OS cells that are positive for Alt-EJ following transfection with (<bold>A</bold>) terminal or (<bold>B</bold>) imbedded determined by flow cytometry. (<bold>CâD</bold>) Percentage of human foreskin keratinocyte (HFK) WT and HFK p300 KO cells that are positive for Alt-EJ following transfection with (<bold>C</bold>) terminal or (<bold>D</bold>) imbedded determined by flow cytometry. (<bold>EâF</bold>) Percentage of HFK cells treated with DMSO or CCS1477 (1 Î¼M) that are positive for Alt-EJ following transfection with (<bold>E</bold>) terminal or (<bold>F</bold>) imbedded determined by flow cytometry. All values are represented as mean Â± standard error. The statistical significance of differences between cell lines and treatments were determined using Studentâs t-test. p-Values indicate significant difference between LXSN and 8E6 (<bold>AâB</bold>); WT and p300KO (<bold>CâD</bold>); and DMSO and CCS1477 treatment (<bold>EâF</bold>). Twenty thousand cells were counted for each of three independent flow cytometry experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81923-fig8-v3.tif"/></fig></sec><sec id="s2-6"><title>DNA-PKcs inhibition prevents the formation of RAD51 foci in G1 that is caused by loss of p300</title><p>We next confirmed that the ability of 8E6 to allow RAD51 foci to form in G1 was blocked by DNA-PKcs inhibition in U2OS cells (<xref ref-type="fig" rid="fig9">Figure 9AâB</xref>). Consistent with a p300-dependent mechanism, RAD51 foci were more likely to occur in G1 when DNA-PKcs was inhibited in U2OS LXSN and U2OS 8E6Î132â136 cells. Further confirming a p300-dependent mechanism of action, HFK without p300 displayed an increased frequency of RAD51 staining in G1 that could be overcome by DNA-PKcs inhibition (<xref ref-type="fig" rid="fig9">Figure 9CâD</xref>). As a final confirmation of the p300 dependence of this phenotype, we treated N/TERT HFKs with 1 ÂµM of CCS1477 to block p300 activity. Inhibition of p300 alone increased the frequency of RAD51 staining in G1 as did DNA-PKcs inhibition alone (<xref ref-type="fig" rid="fig9">Figure 9EâF</xref>). However, RAD51 staining in G1 was not increased by their dual application.</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>NU7441 abrogates RAD51 in G1 induced by losing p300 activity.</title><p>(<bold>AâB</bold>) Percentage of U2OS treated with DMSO or NU7441 (1 Î¼M) in G1 that RAD51 staining after zeocin treatment (10 Âµg/mL, 10 min) as determined by (<bold>A</bold>) cyclin E staining or (<bold>B</bold>) flow cytometry. (<bold>CâD</bold>) Percentage of human foreskin keratinocyte (HFK) cells treated with DMSO or NU7441 in G1 that RAD51 staining after zeocin treatment determined by (<bold>C</bold>) cyclin E staining or (<bold>D</bold>) flow cytometry. (<bold>EâF</bold>) Percentage of HFK cells treated with DMSO, CCS1477 (1 Î¼M), or NU7441 in G1 that RAD51 staining after zeocin treatment determined by (<bold>E</bold>) cyclin E staining or (<bold>F</bold>) flow cytometry. All values are represented as mean Â± standard error. The statistical significance of differences between treatments were determined using Studentâs t-test. p-Values indicate significant difference between DMSO and NU7441 with same cell line. At least 150 cells were counted over three independent experiments for microscopy. Twenty thousand cells were counted for each of three independent flow cytometry experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81923-fig9-v3.tif"/></fig></sec><sec id="s2-7"><title>Alt-EJ deletions occur at a higher frequency in 8E6 expressing cells</title><p>HFK cells were transfected with the 8E6 expression vector or empty vector and equally passaged under selective pressure to establish HFK 8E6 versus control HFK LXSN cell lines. These were subjected to whole genome sequencing to determine the type and frequency of mutations accumulated within each cell type. This yielded 933,163,972 high-quality paired-end sequence reads for LXSN and 624,472,714 reads for 8E6 (<xref ref-type="table" rid="table1">Table 1</xref>). Normalizing LXSN reads to the same number as 8E6 and alignment to the human genome yielded 92.4% genome coverage for both and slightly more read depth for LXSN (mean 45.4 for LXSN compared to 44.6 for 8E6) (<xref ref-type="table" rid="table2">Table 2</xref>). Variant calling including single-nucleotide polymorphisms (SNPs) and insertions or deletions (indels) were also more for LXSN cells than 8E6 expressing cells with one variation every 3 kb in LXSN compared to one every 3333 bases in 8E6 (<xref ref-type="table" rid="table3">Table 3</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Read counts.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">LXSN</th><th align="left" valign="bottom">Reads</th><th align="left" valign="bottom">Quality reads</th><th align="left" valign="bottom">8E6</th><th align="left" valign="bottom">Reads</th><th align="left" valign="bottom">Quality reads</th></tr></thead><tbody><tr><td align="left" valign="bottom">R1</td><td align="char" char="." valign="bottom">480,023,697</td><td align="char" char="." valign="bottom">466,581,986</td><td align="left" valign="bottom">R1</td><td align="char" char="." valign="bottom">326,902,764</td><td align="char" char="." valign="bottom">312,236,357</td></tr><tr><td align="left" valign="bottom">R2</td><td align="char" char="." valign="bottom">480,023,697</td><td align="char" char="." valign="bottom">466,581,986</td><td align="left" valign="bottom">R2</td><td align="char" char="." valign="bottom">326,902,764</td><td align="char" char="." valign="bottom">312,236,357</td></tr></tbody></table></table-wrap><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Genome coverage of reads normalized to 624,472,714.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Samples</th><th align="left" valign="bottom">Mean read depth</th><th align="left" valign="bottom">Coverage (%)</th><th align="left" valign="bottom">Reads mapped (%)</th></tr></thead><tbody><tr><td align="left" valign="bottom">LXSN</td><td align="char" char="." valign="bottom">45.4</td><td align="char" char="." valign="bottom">92.4</td><td align="char" char="." valign="bottom">99.74</td></tr><tr><td align="char" char="." valign="bottom">8E6</td><td align="char" char="." valign="bottom">44.6</td><td align="char" char="." valign="bottom">92.4</td><td align="char" char="." valign="bottom">99.76</td></tr></tbody></table></table-wrap><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Summary of variant analysis reads normalized to 624,472,714.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Genome (GRCh37)</th><th align="left" valign="bottom">LXSN</th><th align="left" valign="bottom">8E6</th></tr></thead><tbody><tr><td align="left" valign="bottom">Number of variants processed</td><td align="left" valign="bottom">1,031,891</td><td align="left" valign="bottom">928,763</td></tr><tr><td align="left" valign="bottom">Number of effects</td><td align="left" valign="bottom">2,514,053</td><td align="left" valign="bottom">2,251,061</td></tr><tr><td align="left" valign="bottom">Genome total length</td><td align="left" valign="bottom">3,234,834,690</td><td align="left" valign="bottom">3,234,834,690</td></tr><tr><td align="left" valign="bottom">Genome effective length</td><td align="left" valign="bottom">3,095,677,413</td><td align="left" valign="bottom">3,095,677,413</td></tr><tr><td align="left" valign="bottom">Variant rate</td><td align="left" valign="bottom">1 variant every 3000 bases</td><td align="left" valign="bottom">1 variant every 3333 bases</td></tr><tr><td align="left" valign="bottom">Number of annotated genes</td><td align="left" valign="bottom">71,845</td><td align="left" valign="bottom">71,078</td></tr><tr><td align="left" valign="bottom">Insertions</td><td align="left" valign="bottom">476,516</td><td align="left" valign="bottom">431,055</td></tr><tr><td align="left" valign="bottom">Deletions</td><td align="left" valign="bottom">555,375</td><td align="left" valign="bottom">497,708</td></tr></tbody></table></table-wrap><p>Repair by Alt-EJ can frequently result in indels with characteristic sequence signatures of flanking microhomology. Using previously established algorithms to identify such characteristic indels (<xref ref-type="bibr" rid="bib35">McIntosh et al., 2020</xref>), we quantified the accumulation of Alt-EJ DNA scars in 8E6 cells compared to LXSN control cells. Counting mutations unique to both LXSN and 8E6 cells, this quantified the frequency of short and long deletions with increasing stretches of microhomology up to 20 bp (<xref ref-type="table" rid="table4 table5 table6">Tables 4â6</xref>, <xref ref-type="table" rid="table7 table8">Tables 7 and 8</xref>); small insertions (&lt;5 bp) resulting from templated synthesis in trans previously reported in <italic>Drosophila</italic> (<xref ref-type="table" rid="table4 table7">Tables 4 and 7</xref>, <xref ref-type="table" rid="table9">Table 9</xref>); or large insertions (â¥18 bp) (<xref ref-type="table" rid="table4 table10">Tables 4 and 10</xref>) resulting from templated synthesis in cis (snapback synthesis) described in mouse embryonic stem (ES) cells. Deletions represented the most abundant Alt-EJ mutations accumulating in both cell lines. Despite a larger number of annotated indels unique to LXSN (168,005 for LXSN compared to 104,322 for 8E6), this revealed a significantly higher frequency of accumulated short deletions (2â29 bp) in the 8E6 cell line (86.75% in 8E6 compared to 82.33% in LXSN, p-value = 2.2e-16). The frequency of short Alt-EJ type deletions was most significant for deletions with short (â¤10 bp) stretches of flanking microhomology (<xref ref-type="table" rid="table4">Table 4</xref>). This trend was similar for long deletions (30â500 bp), albeit not statistically significant (<xref ref-type="table" rid="table5">Table 5</xref>, <xref ref-type="table" rid="table6">Table 6</xref>). Accumulating insertions both small and large bearing Alt-EJ signatures were far less in frequency in both 8E6 and LXSN cell lines though significantly more in LXSN cells (<xref ref-type="table" rid="table7 table8">Tables 7 and 8</xref>) consistent with more non-Alt-EJ mutations annotated in LXSN.</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Characteristics of microhomology (Mh) mediated short deletions (2â29 bp) in HFK 8E6 cells.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">LXSNtotal</th><th align="left" valign="bottom">Minimum Mh (bp)</th><th align="left" valign="bottom">Alt-EJ</th><th align="left" valign="bottom">Frequency(%)</th><th align="left" valign="bottom">E6total</th><th align="left" valign="bottom">Minimum Mh (bp)</th><th align="left" valign="bottom">Alt-EJ</th><th align="left" valign="bottom">Frequency(%)</th><th align="left" valign="bottom">p-Value</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom">49,119</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">40,440</td><td align="char" char="." valign="bottom">82</td><td align="char" char="." valign="bottom">32,763</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">28,425</td><td align="char" char="." valign="bottom">87</td><td align="char" char="." valign="bottom">2.2e-16</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">22,580</td><td align="char" char="." valign="bottom">46</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">15,512</td><td align="char" char="." valign="bottom">47</td><td align="char" char="." valign="bottom">1.13e-4</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">4</td><td align="char" char="." valign="bottom">16,370</td><td align="char" char="." valign="bottom">33</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">4</td><td align="char" char="." valign="bottom">11,337</td><td align="char" char="." valign="bottom">35</td><td align="char" char="." valign="bottom">1.61e-4</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">5</td><td align="char" char="." valign="bottom">10,826</td><td align="char" char="." valign="bottom">22</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">5</td><td align="char" char="." valign="bottom">7664</td><td align="char" char="." valign="bottom">23</td><td align="char" char="." valign="bottom">6.06e-6</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">6</td><td align="char" char="." valign="bottom">8918</td><td align="char" char="." valign="bottom">18</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">6</td><td align="char" char="." valign="bottom">6468</td><td align="char" char="." valign="bottom">20</td><td align="char" char="." valign="bottom">1.33e-8</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">7</td><td align="char" char="." valign="bottom">7076</td><td align="char" char="." valign="bottom">14</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">7</td><td align="char" char="." valign="bottom">5037</td><td align="char" char="." valign="bottom">15</td><td align="char" char="." valign="bottom">1.37e-4</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">8</td><td align="char" char="." valign="bottom">6243</td><td align="char" char="." valign="bottom">13</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">8</td><td align="char" char="." valign="bottom">4557</td><td align="char" char="." valign="bottom">14</td><td align="char" char="." valign="bottom">7.16e-7</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">9</td><td align="char" char="." valign="bottom">4870</td><td align="char" char="." valign="bottom">10</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">9</td><td align="char" char="." valign="bottom">3507</td><td align="char" char="." valign="bottom">11</td><td align="char" char="." valign="bottom">2.72e-4</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">10</td><td align="char" char="." valign="bottom">4392</td><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">10</td><td align="char" char="." valign="bottom">3165</td><td align="char" char="." valign="bottom">10</td><td align="char" char="." valign="bottom">5.22e-4</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">11</td><td align="char" char="." valign="bottom">3621</td><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">11</td><td align="char" char="." valign="bottom">2498</td><td align="char" char="." valign="bottom">8</td><td align="char" char="." valign="bottom">0.1825</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">12</td><td align="char" char="." valign="bottom">3234</td><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">12</td><td align="char" char="." valign="bottom">2292</td><td align="char" char="." valign="bottom">7</td><td align="char" char="." valign="bottom">0.0222</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">13</td><td align="char" char="." valign="bottom">2448</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">13</td><td align="char" char="." valign="bottom">1700</td><td align="char" char="." valign="bottom">5</td><td align="char" char="." valign="bottom">0.1957</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">14</td><td align="char" char="." valign="bottom">2211</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">14</td><td align="char" char="." valign="bottom">1522</td><td align="char" char="." valign="bottom">5</td><td align="char" char="." valign="bottom">0.3412</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">15</td><td align="char" char="." valign="bottom">1847</td><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">15</td><td align="char" char="." valign="bottom">1185</td><td align="char" char="." valign="bottom">4</td><td align="char" char="." valign="bottom">0.2958</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">16</td><td align="char" char="." valign="bottom">1602</td><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">16</td><td align="char" char="." valign="bottom">1060</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">0.8522</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">17</td><td align="char" char="." valign="bottom">1238</td><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">17</td><td align="char" char="." valign="bottom">763</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">0.0861</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">18</td><td align="char" char="." valign="bottom">1083</td><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">18</td><td align="char" char="." valign="bottom">682</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">0.2440</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">19</td><td align="char" char="." valign="bottom">866</td><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">19</td><td align="char" char="." valign="bottom">509</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">0.0240</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">20</td><td align="char" char="." valign="bottom">765</td><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">20</td><td align="char" char="." valign="bottom">467</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">0.1358</td></tr></tbody></table></table-wrap><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>Characteristics of microhomology (Mh) long deletions (30â500 bp) in human foreskin keratinocyte (HFK) 8E6 cells.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">LXSNtotal</th><th align="left" valign="bottom">Minimum Mh (bp)</th><th align="left" valign="bottom">Alt-EJ</th><th align="left" valign="bottom">Frequency(%)</th><th align="left" valign="bottom">E6total</th><th align="left" valign="bottom">Minimum Mh (bp)</th><th align="left" valign="bottom">Alt-EJ</th><th align="left" valign="bottom">Frequency(%)</th><th align="left" valign="bottom">p-Value</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom">2612</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">1959</td><td align="char" char="." valign="bottom">75</td><td align="char" char="." valign="bottom">1168</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">888</td><td align="char" char="." valign="bottom">76</td><td align="char" char="." valign="bottom">0.5247</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">1844</td><td align="char" char="." valign="bottom">71</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">842</td><td align="char" char="." valign="bottom">72</td><td align="char" char="." valign="bottom">0.3704</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">4</td><td align="char" char="." valign="bottom">1735</td><td align="char" char="." valign="bottom">66</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">4</td><td align="char" char="." valign="bottom">782</td><td align="char" char="." valign="bottom">67</td><td align="char" char="." valign="bottom">0.7790</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">5</td><td align="char" char="." valign="bottom">1689</td><td align="char" char="." valign="bottom">65</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">5</td><td align="char" char="." valign="bottom">765</td><td align="char" char="." valign="bottom">65</td><td align="char" char="." valign="bottom">0.6460</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">6</td><td align="char" char="." valign="bottom">1635</td><td align="char" char="." valign="bottom">63</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">6</td><td align="char" char="." valign="bottom">722</td><td align="char" char="." valign="bottom">62</td><td align="char" char="." valign="bottom">0.6734</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">7</td><td align="char" char="." valign="bottom">1594</td><td align="char" char="." valign="bottom">61</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">7</td><td align="char" char="." valign="bottom">693</td><td align="char" char="." valign="bottom">59</td><td align="char" char="." valign="bottom">0.3429</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">8</td><td align="char" char="." valign="bottom">1536</td><td align="char" char="." valign="bottom">59</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">8</td><td align="char" char="." valign="bottom">673</td><td align="char" char="." valign="bottom">58</td><td align="char" char="." valign="bottom">0.5171</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">9</td><td align="char" char="." valign="bottom">1487</td><td align="char" char="." valign="bottom">57</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">9</td><td align="char" char="." valign="bottom">656</td><td align="char" char="." valign="bottom">56</td><td align="char" char="." valign="bottom">0.6868</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">10</td><td align="char" char="." valign="bottom">1433</td><td align="char" char="." valign="bottom">55</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">10</td><td align="char" char="." valign="bottom">634</td><td align="char" char="." valign="bottom">54</td><td align="char" char="." valign="bottom">0.7669</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">11</td><td align="char" char="." valign="bottom">1381</td><td align="char" char="." valign="bottom">53</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">11</td><td align="char" char="." valign="bottom">616</td><td align="char" char="." valign="bottom">53</td><td align="char" char="." valign="bottom">0.9684</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">12</td><td align="char" char="." valign="bottom">1332</td><td align="char" char="." valign="bottom">51</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">12</td><td align="char" char="." valign="bottom">596</td><td align="char" char="." valign="bottom">51</td><td align="char" char="." valign="bottom">1.0000</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">13</td><td align="char" char="." valign="bottom">1286</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">13</td><td align="char" char="." valign="bottom">568</td><td align="char" char="." valign="bottom">49</td><td align="char" char="." valign="bottom">0.7580</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">14</td><td align="char" char="." valign="bottom">1245</td><td align="char" char="." valign="bottom">48</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">14</td><td align="char" char="." valign="bottom">543</td><td align="char" char="." valign="bottom">46</td><td align="char" char="." valign="bottom">0.5265</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">15</td><td align="char" char="." valign="bottom">1202</td><td align="char" char="." valign="bottom">46</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">15</td><td align="char" char="." valign="bottom">530</td><td align="char" char="." valign="bottom">45</td><td align="char" char="." valign="bottom">0.7410</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">16</td><td align="char" char="." valign="bottom">1168</td><td align="char" char="." valign="bottom">45</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">16</td><td align="char" char="." valign="bottom">505</td><td align="char" char="." valign="bottom">43</td><td align="char" char="." valign="bottom">0.4172</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">17</td><td align="char" char="." valign="bottom">1131</td><td align="char" char="." valign="bottom">43</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">17</td><td align="char" char="." valign="bottom">485</td><td align="char" char="." valign="bottom">42</td><td align="char" char="." valign="bottom">0.3249</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">18</td><td align="char" char="." valign="bottom">1089</td><td align="char" char="." valign="bottom">42</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">18</td><td align="char" char="." valign="bottom">468</td><td align="char" char="." valign="bottom">40</td><td align="char" char="." valign="bottom">0.3673</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">19</td><td align="char" char="." valign="bottom">1051</td><td align="char" char="." valign="bottom">40</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">19</td><td align="char" char="." valign="bottom">451</td><td align="char" char="." valign="bottom">39</td><td align="char" char="." valign="bottom">0.3644</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">20</td><td align="char" char="." valign="bottom">1010</td><td align="char" char="." valign="bottom">39</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">20</td><td align="char" char="." valign="bottom">433</td><td align="char" char="." valign="bottom">37</td><td align="char" char="." valign="bottom">0.3697</td></tr></tbody></table></table-wrap><table-wrap id="table6" position="float"><label>Table 6.</label><caption><title>Filtered variants for Alt-EJ analyses.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">LXSN</th><th align="left" valign="bottom">8E6</th></tr></thead><tbody><tr><td align="left" valign="bottom">Pre-filtered</td><td align="char" char="." valign="bottom">879,302</td><td align="char" char="." valign="bottom">820,766</td></tr><tr><td align="left" valign="bottom">Unique INDELs</td><td align="char" char="." valign="bottom">168,005</td><td align="char" char="." valign="bottom">104,322</td></tr></tbody></table></table-wrap><table-wrap id="table7" position="float"><label>Table 7.</label><caption><title>Short deletions bearing microhomology signatures of Alt-EJ.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Sample</th><th align="left" valign="bottom">Short deletions (2â29 bp)</th><th align="left" valign="bottom">Matching Alt-EJ</th><th align="left" valign="bottom">Frequency (%)</th><th align="left" valign="bottom">p-Value</th></tr></thead><tbody><tr><td align="left" valign="bottom">LXSN</td><td align="char" char="." valign="bottom">49,119</td><td align="char" char="." valign="bottom">40,440</td><td align="char" char="." valign="bottom">82.33</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">8E6</td><td align="char" char="." valign="bottom">32,763</td><td align="char" char="." valign="bottom">28,425</td><td align="char" char="." valign="bottom">86.75</td><td align="char" char="hyphen" valign="bottom">2.2e-16</td></tr></tbody></table></table-wrap><table-wrap id="table8" position="float"><label>Table 8.</label><caption><title>Long deletions bearing microhomology signatures of Alt-EJ.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Sample</th><th align="left" valign="bottom">Long deletions (â¥30 bp)</th><th align="left" valign="bottom">Matching Alt-EJ</th><th align="left" valign="bottom">Frequency (%)</th><th align="left" valign="bottom">p-Value</th></tr></thead><tbody><tr><td align="left" valign="bottom">LXSN</td><td align="char" char="." valign="bottom">2612</td><td align="char" char="." valign="bottom">1959</td><td align="char" char="." valign="bottom">75.00</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">8E6</td><td align="char" char="." valign="bottom">1168</td><td align="char" char="." valign="bottom">888</td><td align="char" char="." valign="bottom">76.03</td><td align="char" char="." valign="bottom">0.5247</td></tr></tbody></table></table-wrap><table-wrap id="table9" position="float"><label>Table 9.</label><caption><title>Short insertions bearing microhomology signatures of Alt-EJ.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Sample</th><th align="left" valign="bottom">Short insertions (&lt;5 bp)</th><th align="left" valign="bottom">Matching Alt-EJ</th><th align="left" valign="bottom">Frequency (%)</th><th align="left" valign="bottom">p-Value</th></tr></thead><tbody><tr><td align="left" valign="bottom">LXSN</td><td align="char" char="." valign="bottom">50,390</td><td align="char" char="." valign="bottom">959</td><td align="char" char="." valign="bottom">1.90</td><td align="char" char="hyphen" valign="bottom">5.62e-10</td></tr><tr><td align="char" char="." valign="bottom">8E6</td><td align="char" char="." valign="bottom">27,611</td><td align="char" char="." valign="bottom">367</td><td align="char" char="." valign="bottom">1.33</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><table-wrap id="table10" position="float"><label>Table 10.</label><caption><title>Long insertions bearing microhomology signatures of Alt-EJ.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Sample</th><th align="left" valign="bottom">Long insertions (â¥18 bp)</th><th align="left" valign="bottom">Matching Alt-EJ</th><th align="left" valign="bottom">Frequency %</th><th align="left" valign="bottom">p-Value</th></tr></thead><tbody><tr><td align="left" valign="bottom">LXSN</td><td align="char" char="." valign="bottom">5485</td><td align="char" char="." valign="bottom">1068</td><td align="char" char="." valign="bottom">19.47</td><td align="char" char="hyphen" valign="bottom">1.547e-05</td></tr><tr><td align="char" char="." valign="bottom">8E6</td><td align="char" char="." valign="bottom">2545</td><td align="char" char="." valign="bottom">392</td><td align="char" char="." valign="bottom">15.40</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We have previously shown that 8E6 attenuates the two most prominent DSB pathways (HR and NHEJ) (<xref ref-type="bibr" rid="bib19">Hu et al., 2020</xref>; <xref ref-type="bibr" rid="bib58">Wallace et al., 2015</xref>). However, 8E6 delays rather than abrogates DSB repair, leaving the question of how DSBs are repaired in cells expressing 8E6. Here, we show that 8E6 promotes DSB repair via Alt-EJ (<xref ref-type="fig" rid="fig10">Figure 10</xref>). Because Alt-EJ can be accomplished using different sets of repair factors, we used small molecule inhibitors to determine which Alt-EJ components were most essential for DSB repair in 8E6 expressing cells. This analysis demonstrated that in HFK 8E6 cells, DSBs become three- to fourfold more persistent when PARP1 is inhibited but only ~1.5-fold more persistent when POLÎ¸ is inhibited. Thus, 8E6 promotes DSB repair that is dependent on PARP1 and to a lesser extent on POLÎ¸.</p><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>Alternative end joining (Alt-EJ) repairs double strand breaks (DSBs) in cells expressing 8E6.</title><p>(<bold>i</bold>) DSB occurs in G1 phase in cells expressing 8E6. (<bold>ii</bold>) Non-homologous end joining (NHEJ) initiates with auto-phosphorated DNA-dependent protein kinase catalytic subunit (DNA-PKcs). (<bold>iii</bold>) 8E6 stalls NHEJ by degrading p300 (<xref ref-type="bibr" rid="bib19">Hu et al., 2020</xref>). (<bold>iv</bold>) Homologous recombination (HR) initiates and fails at the site of failed NHEJ (<xref ref-type="bibr" rid="bib22">Hu and Wallace, 2022c</xref>). (<bold>v</bold>) Finally, PARP-1-dependent Alt-EJ repairs the DSB, which lead to microhomology mediated indels.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81923-fig10-v3.tif"/></fig><p>Moreover, we show that HFK 8E6 cells can be further induced to repair DSBs via Alt-EJ by the inhibition of an early step during NHEJ (DNA-PKcs) but not a later step in the pathway (Ligase IV). The increased use of Alt-EJ induced by DNA-PKcs inhibition prevented 8E6 from generating previously described DSB repair defects including the formation of RAD51 foci in G1 and delayed DSB repair. We also show that DNA-PKcs inhibition does not cause an increase in HR. Further, we provide mechanistic insight into these phenomena by showing that 8E6 promotes Alt-EJ via p300 degradation and that DNA-PKcs inhibition can prevent RAD51 foci from forming in G1 because of p300 loss. Finally, we provide whole genome sequence analysis that demonstrates 8E6 expression results in a significantly higher frequency of short deletions bearing microhomology signatures of Alt-EJ. These Alt-EJ deletions appear more frequently as short deletions (2â29 bp) bearing short stretches of microhomology (2â10 bp) (<xref ref-type="table" rid="table4">Table 4</xref>).</p><p>There are some limitations to this study. This includes potential off target activity of inhibitors. Further complicating the analysis, many DNA repair factors (e.g., PARP1) are involved in more than one repair pathways. We also acknowledge that U2OS may contain mutations (such as an ATR mutation) that change the mechanisms of DSB repair pathway choice (<xref ref-type="bibr" rid="bib15">Elbakry et al., 2021</xref>; <xref ref-type="bibr" rid="bib26">JuhÃ¡sz et al., 2018</xref>). However, the known ways that 8E6 alters DSB repair are consistent in U2OS and primary (HFK) cells, suggesting that results obtained in U2OS cells can be extrapolated to other cell types (<xref ref-type="bibr" rid="bib19">Hu et al., 2020</xref>; <xref ref-type="bibr" rid="bib58">Wallace et al., 2015</xref>). 8E6 was also expressed with the other HPV8 early genes as would be the case during a natural infection. We are currently working to determine the extent that these other early genes augment or suppress 8E6-induced changes in DSB repair.</p><p>Many of the findings in this study are consistent with the existing hypotheses about DSB repair and the potential for beta-HPV infections to promote NMSCs (<xref ref-type="bibr" rid="bib16">Gheit, 2019</xref>; <xref ref-type="bibr" rid="bib28">Kremsdorf et al., 1982</xref>; <xref ref-type="bibr" rid="bib41">Pfister, 2003</xref>). For example, our data in vector control (LXSN) cells show that Alt-EJ is increased when NHEJ is inhibited and that DSB repair is not significantly delayed by inhibition of Alt-EJ. This is compatible with the idea that Alt-EJ is primarily used when there are defects in either HR or NHEJ (<xref ref-type="bibr" rid="bib13">Deriano and Roth, 2013</xref>; <xref ref-type="bibr" rid="bib48">Simsek and Jasin, 2010</xref>; <xref ref-type="bibr" rid="bib52">Truong et al., 2013</xref>). Similarly, by showing that 8E6 promotes Alt-EJ, a mutagenic DSB repair pathway, we provide evidence in support of the idea that transient Î²-HPV infections may promote tumorigenesis by causing mutations (<xref ref-type="bibr" rid="bib51">Tommasino, 2019</xref>; <xref ref-type="bibr" rid="bib55">Viarisio et al., 2018</xref>; <xref ref-type="bibr" rid="bib61">Wendel and Wallace, 2017</xref>). We also show that p300 restricts DSB repair by Alt-EJ and that at least some of the DSB repair defects caused by p300 loss or 8E6 expression can be overcome by inhibition of DNA-PKcs. Does DNA-PKcs inhibition represent a feasible approach to block the increased mutagenesis associated with 8E6 expression? Or on the contrary, does DNA-PKcs inhibition promote more mutations generated by Alt-EJ?</p><p>Induction of Alt-EJ is not limited to HPV8 as a recent report demonstrated that a different HPV protein from a different genus of HPV (HPV16 E7) also increases the use of Alt-EJ (<xref ref-type="bibr" rid="bib29">Leeman et al., 2019</xref>). Further, HPV positive head and neck squamous cell carcinomas and other cancers with downregulated TGF-b signaling have an elevated frequency of mutations with signatures of repair by Alt-EJ (<xref ref-type="bibr" rid="bib31">Liu et al., 2018</xref>; <xref ref-type="bibr" rid="bib32">Liu et al., 2021</xref>). We show that 8E6 increases the frequency of short deletions with very short stretches of flanking microhomology. Thus, the ability to promote Alt-EJ seems to have evolved in two separate genes in the HPV family (once in HPV16 E7 and once in HPV8 E6) (<xref ref-type="bibr" rid="bib29">Leeman et al., 2019</xref>). Why would these viruses both evolve ways to promote Alt-EJ? Perhaps, this can be linked to their ability to impair HR and/or NHEJ (<xref ref-type="bibr" rid="bib19">Hu et al., 2020</xref>; <xref ref-type="bibr" rid="bib58">Wallace et al., 2015</xref>). Unrepaired DSBs are highly lethal, thus we infer a strong selective pressure for HPV (a non-lytic virus) to find alternative way(s) to repair DSBs.</p><p>The data presented here invoke other interesting thoughts. Do HPV8 infections leave Alt-EJ signatures during natural infections? If so, can Alt-EJ signatures be used to provide evidence that naturally occurring beta-HPVs cause mutations? The ability to identify mutations caused by past transient beta-HPV infections would provide the long-sought after evidence that these infections permanently harm host cells.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HFK</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Derived from neonatal foreskins</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">N/TERT HFK</td><td align="left" valign="bottom">Michael Underbrink (PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/18256157/">18256157</ext-link>)</td><td align="left" valign="bottom"/><td align="left" valign="bottom">N/TERT immortalized HFK</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">U2OS</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/10541549/">10541549</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell line used to measure HR frequency</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Alt-EJ reporter</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">#113619</td><td align="left" valign="bottom">Alt-EJ reporter using 4 nt microhomology</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Alt-EJ reporter (5â end)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">#113620</td><td align="left" valign="bottom">sgRNA/CAS9 to induce the 5â end DSB</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Alt-EJ reporter (terminal)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom"><bold>#113625</bold><break/>#113625</td><td align="left" valign="bottom">sgRNA/CAS9 to induce the DSB at the edge of the microhomology</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Alt-EJ reporter (imbedded)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">#113626</td><td align="left" valign="bottom">sgRNA/CAS9 to induce the DSB 8 nt upstream of the microhomology</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-RAD51<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab1837</td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-cyclin E (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="char" char="." valign="bottom">4132S</td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-pH2AX S139 (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="char" char="." valign="bottom">9718S</td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-cyclin A (Mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab39</td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 594 (Goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">A11012</td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 488 (Goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">A11001</td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">CCS1477</td><td align="left" valign="bottom">Chemietek</td><td align="left" valign="bottom">CT-CCS1477</td><td align="left" valign="bottom">P300 inhibitor</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">NU7441</td><td align="left" valign="bottom">Selleckchem</td><td align="left" valign="bottom">S2638</td><td align="left" valign="bottom">DNA-PKcs inhibitor</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Zeocin</td><td align="left" valign="bottom">Alfa Aesar</td><td align="left" valign="bottom">J67140-XF</td><td align="left" valign="bottom">Used to induce DSBs</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ART558</td><td align="left" valign="bottom">MedChem Express</td><td align="left" valign="bottom">HY-141520</td><td align="left" valign="bottom">Pol Theta inhibitor</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DAPI stain</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">D1306</td><td align="left" valign="bottom">IF (10 ÂµM)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">NUCLEAR-ID Red</td><td align="left" valign="bottom">Enzo Life Science</td><td align="left" valign="bottom">ENZ-52406</td><td align="left" valign="bottom">Flow cytometry (1:1000)</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom">ImageJ (<ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</ext-link>)</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Version 2.3.0</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism</td><td align="left" valign="bottom">GraphPad Prism (<ext-link ext-link-type="uri" xlink:href="https://graphpad.com">https://graphpad.com</ext-link>)</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Version 9.0.0</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture and reagents</title><p>Primary HFKs were derived from neonatal human foreskins. Immortalized human foreskin keratinocytes (N/TERT HFK) provided by Michael Underbrink (University of Texas Medical Branch). Both HFKs were grown in EpiLife medium (MEPICF500, Gibco), supplemented with 60 ÂµM calcium chloride (MEPICF500, Gibco), human keratinocyte growth supplement (MEPICF500, Gibco), and 1% penicillin-streptomycin (PSL02-6X100ML, Caisson). Both keratinocyte cell lines were derived from different donors. They were maintained at low passage number (&lt;20 passages) for all experiments described in this manuscript. Their identity was confirmed by morphology and growth in selective media. Only keratinocytes are viable in EpiLife media.</p><p>U2OS were maintained in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin. Zeocin (J67140-XF, Alfa Aesar) was used to induce DSBs (10 Âµg/mL, 10 min). Their identity was confirmed by the presence of the DR-GFP construct used to measure HR. This reporter cassette only exists in these cells within our lab. 8E6 expression (or lack thereof) was confirmed by rtPCR. All cell lines in this study underwent regular mycoplasma testing. NU7441 (S2638, Selleckchem) was used to inhibit DNA-PKcs phosphorylation (1 ÂµM) and verify the pDNA-PKcs antibody. siRNA DNA-PKcs was used to further validate pDNA-PKcs antibody. KU55933 (Sigma-Aldrich, SML1109) was used to validate RAD51 antibody as previously described (<xref ref-type="bibr" rid="bib2">Bakr et al., 2015</xref>). CCS1477 (CT-CCS1477, Chemietek) was used to inhibit p300 activity (1 ÂµM). ART558 (HY-141520, MedChem Express) was used to inhibit Pol Theta activity. Alt-EJ plasmids (#113619, #113620, #113625, #113626, Addgene) were used to measure Alt-EJ efficiency.</p></sec><sec id="s4-2"><title>Immunofluorescence microscopy</title><p>Cells were seeded onto either 96-well glass-bottom plates and grown overnight. Cells treated with zeocin (10 Î¼g/mL, 10 min) were fixed with 4% paraformaldehyde. Then, 0.1% Triton-X was used to permeabilize the cells, followed by blocking with 3% bovine serum albumin. Cells were then incubated with the following antibodies: RAD51 (ab1837, Abcam, 1:200), cyclin E (4132S, Cell Signaling), pH2AX S139 (9718S, Cell Signaling), and cyclin A (ab39, Abcam). The cells were washed and stained with the appropriate secondary antibodies: Alexa Fluor 594 (red) goat anti-rabbit (A11012, Thermo Fisher Scientific), Alexa Fluor 488 (green) goat anti-mouse (A11001, Thermo Fisher Scientific). After washing, the cells were stained with 10 ÂµM DAPI in PBS and visualized with the Zeiss LSM 770 microscope. Images were analyzed using the ImageJ techniques previously described (<xref ref-type="bibr" rid="bib36">Murthy et al., 2018</xref>). Cyclin E intensity was measured for each cell. Average cyclin E intensity of cells grown in media without growth factor for 4 hr was used to define the threshold of cyclin E positive.</p></sec><sec id="s4-3"><title>Flow cytometry</title><p>Cells were collected from 6 cm plates, at about 80â90% confluence, by using trypsinization. Cells were washed with cold PBS and fixed with 95% cold ethanol for 10 min at â20Â°C. Cells were stained with anti-RAD51 antibody (ab1837, Abcam, 1:100) and Alexa Fluor 488 goat anti-mouse (A11001, Thermo Fisher Scientific). After washing, cells were resuspended in 200 ÂµL PBS and NUCLEAR-ID Red DNA stain (ENZ-52406, Enzo Life Science), and incubated in the dark at room temperature for 30 min. Samples were analyzed by a BD Accuri C6 Plus Flow Cytometer.</p></sec><sec id="s4-4"><title>Immunoblotting</title><p>After being washed with ice-cold PBS, cells were lysed with RIPA Lysis Buffer (VWRVN653-100ML, VWR Life Science), supplemented with Phosphatase Inhibitor Cocktail 2 (P5726-1ML, Sigma) and Protease Inhibitor Cocktail (B14001, Bimake). The Pierce BCA Protein Assay Kit (89167-794, Thermo Fisher Scientific) was used to determine protein concentration. Equal protein lysates were run on Novex 3â8% Tris-acetate 15 Well Mini Gels (EA03785BOX, Invitrogen) and transferred to Immobilon-P membranes (IPVH00010, Thermo Fisher Scientific). Membranes were then probed with the following primary antibodies: GAPDH (sc-47724, Santa Cruz Biotechnologies, 1:1000) P300 (sc-48343, Santa Cruz Biotechnologies). CAS9 (65832S, Cell Signaling). Pol Theta (PA5-69577, Thermo Fisher Scientific). After exposure to the matching HRP-conjugated secondary antibody, cells were visualized using SuperSignal West Femto Maximum Sensitivity Substrate (34095, Thermo Fisher Scientific).</p></sec><sec id="s4-5"><title>Transfection and Alt-EJ assay</title><p>HFK cells were plated in 3 mL of complete growth medium in a 6 cm plate. Cells were used at 80% confluency. Two Âµg of plasmids were diluted in 200 ÂµL Xfect transfection reagent (631317, Takara). The mixture was incubated at room temperature for 15 min. The transfection mixture was added to each well drop-wise and incubated for 48 hr at 37Â°C. Cells were harvested for flow cytometry analysis.</p></sec><sec id="s4-6"><title>Whole genome sequencing analysis</title><p>HFK cells were transfected with the 8E6 expression vector or empty vector and equally passaged under selective pressure to establish HFK 8E6 versus control HFK LXSN cells. DNA was extracted using Trizol (Invitrogen), libraries were prepared using the Illumina DNA PCR-Free prep kit and sequenced with paired 300-bp v1.5 reads on a Novaseq 6000. All protocols were performed using the standard procedures provided by the manufacturers. Sequences have been deposited in the NCBI SRA database with accession number (PRJNA 856469).</p></sec><sec id="s4-7"><title>Variant calling and Alt-EJ mutational analysis</title><p>Whole genome sequences for passage matched LXSN and 8E6 cell lines were analyzed for indel detection using the best practices for variant discovery analysis outlined by the Broad Institute (<xref ref-type="bibr" rid="bib12">DePristo et al., 2011</xref>). Briefly, reads from the sequenced samples were preprocessed for quality control by removing adapter sequences and low-quality reads (&lt;Q20). Quality paired-end reads from LXSN were normalized to the same number of reads from 8E6 (624,472,714) and both sets were mapped to the human reference genome (GRCh37/hg19) using Burrows-Wheeler Aligner (BWA v0.7.17) (<xref ref-type="bibr" rid="bib30">Li and Durbin, 2010</xref>). Aligned reads were sorted and duplicate reads were removed using Picard-tools (v2.25.5). Raw genomic variants, including SNPs and DNA insertions and deletions (indels), were identified using the GATK HaplotypeCaller algorithm in GATK (v4.1.9.0) (âGenomics in the Cloud [Book]â, n.d.). The identified indels were extracted and filtered for quality with GATK VariantFiltration (QUAL score normalized by allele depth: QD &lt;2.0, Phred-scaled probability: FS &gt;200, and Symmetric odds ratio test: SOR &gt;10), followed by base quality score recalibration using GATK BaseRecalibrator and applied to the aligned bam files. A second round of variant calling (GATK Haplotype Caller) was performed using recalibrated (analysis-ready) SNPs and indels further filtered for quality. SnpEff 5.0 was used to annotate the genetic variants.</p><p>Alt-EJ mutational signatures were counted as previously described (<xref ref-type="bibr" rid="bib35">McIntosh et al., 2020</xref>). Briefly, indels previously identified by the 1000 Genomes Project or shared between LXSN and 8E6 cell lines were removed. Alt-EJ mutational signatures bearing flanking microhomology were then determined in R for small deletions (2â29 bp) and long deletions (30â500 bp), small insertions (&lt;5 bp), and large snap-back insertions (â¥18 bp). For analysis of deletions with microhomology, the sequence adjacent to each deletion was extracted based on the human genome (R package BSgenome.Hsapiens. UCSC.hg19) and annotated according to the number of contiguous matching nucleotides between the deletion and the adjacent sequence, counted from the beginning of each sequence (microhomology). Different microhomology length thresholds (ranging from 2 to 20 bp) were then used to filter the results into Alt-EJ matching deletions unique to each LXSN and E6 cell line.</p><p>To detect synthesis-dependent small insertions, we extracted Â±15 nt surrounding the insertion (from the hg19 human genome) and identified whether there was a repeated sequence either 5â or 3â to the insertion that matched the full insertion and also at least 2 nt on either side. Matches also needed to have a gap of at least 1 nt between the two sequences.</p><p>For synthesis-dependent snapback (large) insertions, only the insertion sequence was considered. Each sequence was compared to its own reverse-complement sequence and any repeats of â¥7 nt also separated by at least 4 nt were labeled as snapback-like. To avoid spurious false negatives, only insertions of at least (2Ã7)+4 = 18 nt were considered.</p></sec><sec id="s4-8"><title>Cell viability assay</title><p>Ten thousand cells/well were seeded on a 96-well plate and grown for 24 hr. Zeocin treatment (10 Î¼g/mL, 10 min) was applied 24 hr after seeding. Then ART558 dose series was added and incubated for 48 hr at 37Â°C. Forty-eight hr after treatment, 10 ÂµL/well of MTT solution (10 mg/mL) was added for 24 hr. Subsequently, wells were incubated with 100 ÂµL solubilization solution for 24 hr and the optical density measured at 640 nm. Doses for ARTT558 : 0, 1, 5, 10, 15, 20, 25, 50.</p></sec><sec id="s4-9"><title>Statistical analysis</title><p>All values are represented as mean Â± standard error (SE). Statistical differences between groups were measured by using Studentâs t-test. p-Values in all experiments were considered significant at less than 0.05. Statistical significance of Alt-EJ mutational frequencies between LSXN and 8E6 in each instance (small or large deletions or insertions) were determined by Fisherâs exact t-test using prop.test in R.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Validation, Investigation, Visualization, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Software, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Methodology</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Writing - review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-81923-mdarchecklist1-v3.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Sequences have been deposited in the NCBI SRA database with accession number (PRJNA 856469).</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Palinski</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Beta human papillomavirus 8E6 promotes alternative end-joining</data-title><source>NCBI BioProject</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA856469">PRJNA856469</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We appreciate KSU-CVM Confocal Core for our immunofluorescence microscopy, Michael Underbrink for providing the TERT-immortalized HFKs, and Jeremy M Stark for providing plasmids of the alt-EJ reporter assay. This research was supported by the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH, P20GM130448); NIH Research Enhancement Award (NCI R15 CA242057 01A1); US Department of Defense (CMDRP PRCRP CA160224 [NW]); and Johnson Cancer Research Center of Kansas State University. We acknowledge the University of Kansas Medical Center Genomics Core for your core support services in publications containing Genomics Core generated data. We would also like to note the following NIH supporting grants â Kansas Intellectual and Developmental Disabilities Research Center (NIH U54 HD 090216), the Molecular Regulation of Cell Development and Differentiation â COBRE (P30 GM122731-03) â the NIH S10 High-End Instrumentation Grant (NIH S10OD021743) and the Frontiers CTSA grant (UL1TR002366) at the University of Kansas Medical Center, Kansas City, KS 66160. We would also like to acknowledge Dr Massimo Tommasino. His kindness and influence will be missed.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ait-Si-Ali</surname><given-names>S</given-names></name><name><surname>Polesskaya</surname><given-names>A</given-names></name><name><surname>Filleur</surname><given-names>S</given-names></name><name><surname>Ferreira</surname><given-names>R</given-names></name><name><surname>Duquet</surname><given-names>A</given-names></name><name><surname>Robin</surname><given-names>P</given-names></name><name><surname>Vervish</surname><given-names>A</given-names></name><name><surname>Trouche</surname><given-names>D</given-names></name><name><surname>Cabon</surname><given-names>F</given-names></name><name><surname>Harel-Bellan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Cbp/P300 histone acetyl-transferase activity is important for the G1/S transition</article-title><source>Oncogene</source><volume>19</volume><fpage>2430</fpage><lpage>2437</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203562</pub-id><pub-id pub-id-type="pmid">10828885</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakr</surname><given-names>A</given-names></name><name><surname>Oing</surname><given-names>C</given-names></name><name><surname>KÃ¶cher</surname><given-names>S</given-names></name><name><surname>Borgmann</surname><given-names>K</given-names></name><name><surname>Dornreiter</surname><given-names>I</given-names></name><name><surname>Petersen</surname><given-names>C</given-names></name><name><surname>Dikomey</surname><given-names>E</given-names></name><name><surname>Mansour</surname><given-names>WY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Involvement of ATM in homologous recombination after end resection and Rad51 nucleofilament formation</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>3154</fpage><lpage>3166</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv160</pub-id><pub-id pub-id-type="pmid">25753674</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedard</surname><given-names>KM</given-names></name><name><surname>Underbrink</surname><given-names>MP</given-names></name><name><surname>Howie</surname><given-names>HL</given-names></name><name><surname>Galloway</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The E6 oncoproteins from human betapapillomaviruses differentially activate telomerase through an E6AP-dependent mechanism and prolong the lifespan of primary keratinocytes</article-title><source>Journal of Virology</source><volume>82</volume><fpage>3894</fpage><lpage>3902</lpage><pub-id pub-id-type="doi">10.1128/JVI.01818-07</pub-id><pub-id pub-id-type="pmid">18256157</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhargava</surname><given-names>R</given-names></name><name><surname>Sandhu</surname><given-names>M</given-names></name><name><surname>Muk</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Vaidehi</surname><given-names>N</given-names></name><name><surname>Stark</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>C-NHEJ without indels is robust and requires synergistic function of distinct XLF domains</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>2484</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-04867-5</pub-id><pub-id pub-id-type="pmid">29950655</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Bouwes Bavinck</surname><given-names>JN</given-names></name><name><surname>Feltkamp</surname><given-names>M</given-names></name><name><surname>Struijk</surname><given-names>L</given-names></name><name><surname>ter Schegget</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Human papillomavirus infection and skin cancer risk in organ transplant recipients</article-title><conf-name>The Journal of Investigative Dermatology. Symposium Proceedings</conf-name><fpage>207</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1046/j.0022-202x.2001.00048.x</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouwes Bavinck</surname><given-names>JN</given-names></name><name><surname>Feltkamp</surname><given-names>MCW</given-names></name><name><surname>Green</surname><given-names>AC</given-names></name><name><surname>Fiocco</surname><given-names>M</given-names></name><name><surname>Euvrard</surname><given-names>S</given-names></name><name><surname>Harwood</surname><given-names>CA</given-names></name><name><surname>Nasir</surname><given-names>S</given-names></name><name><surname>Thomson</surname><given-names>J</given-names></name><name><surname>Proby</surname><given-names>CM</given-names></name><name><surname>Naldi</surname><given-names>L</given-names></name><name><surname>Diphoorn</surname><given-names>JCD</given-names></name><name><surname>Venturuzzo</surname><given-names>A</given-names></name><name><surname>Tessari</surname><given-names>G</given-names></name><name><surname>Nindl</surname><given-names>I</given-names></name><name><surname>Sampogna</surname><given-names>F</given-names></name><name><surname>Abeni</surname><given-names>D</given-names></name><name><surname>Neale</surname><given-names>RE</given-names></name><name><surname>Goeman</surname><given-names>JJ</given-names></name><name><surname>Quint</surname><given-names>KD</given-names></name><name><surname>Halk</surname><given-names>AB</given-names></name><name><surname>Sneek</surname><given-names>C</given-names></name><name><surname>Genders</surname><given-names>RE</given-names></name><name><surname>de Koning</surname><given-names>MNC</given-names></name><name><surname>Quint</surname><given-names>WGV</given-names></name><name><surname>Wieland</surname><given-names>U</given-names></name><name><surname>Weissenborn</surname><given-names>S</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name><name><surname>Pfister</surname><given-names>H</given-names></name><collab>EPI-HPV-UV-CA group</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Human papillomavirus and posttransplantation cutaneous squamous cell carcinoma: a multicenter, prospective cohort study</article-title><source>American Journal of Transplantation</source><volume>18</volume><fpage>1220</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1111/ajt.14537</pub-id><pub-id pub-id-type="pmid">29024374</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunting</surname><given-names>SF</given-names></name><name><surname>CallÃ©n</surname><given-names>E</given-names></name><name><surname>Wong</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>HT</given-names></name><name><surname>Polato</surname><given-names>F</given-names></name><name><surname>Gunn</surname><given-names>A</given-names></name><name><surname>Bothmer</surname><given-names>A</given-names></name><name><surname>Feldhahn</surname><given-names>N</given-names></name><name><surname>Fernandez-Capetillo</surname><given-names>O</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>CX</given-names></name><name><surname>Finkel</surname><given-names>T</given-names></name><name><surname>Nussenzweig</surname><given-names>M</given-names></name><name><surname>Stark</surname><given-names>JM</given-names></name><name><surname>Nussenzweig</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>53Bp1 inhibits homologous recombination in BRCA1-deficient cells by blocking resection of DNA breaks</article-title><source>Cell</source><volume>141</volume><fpage>243</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.03.012</pub-id><pub-id pub-id-type="pmid">20362325</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>JR</given-names></name><name><surname>Taylor</surname><given-names>MRG</given-names></name><name><surname>Boulton</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Playing the end game: DNA double-strand break repair pathway choice</article-title><source>Molecular Cell</source><volume>47</volume><fpage>497</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2012.07.029</pub-id><pub-id pub-id-type="pmid">22920291</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dacus</surname><given-names>D</given-names></name><name><surname>Wallace</surname><given-names>NA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Beta-genus human papillomavirus 8 E6 destabilizes the host genome by promoting p300 degradation</article-title><source>Viruses</source><volume>13</volume><elocation-id>1662</elocation-id><pub-id pub-id-type="doi">10.3390/v13081662</pub-id><pub-id pub-id-type="pmid">34452526</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>AJ</given-names></name><name><surname>Chi</surname><given-names>L</given-names></name><name><surname>So</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>KJ</given-names></name><name><surname>Mori</surname><given-names>E</given-names></name><name><surname>Fattah</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Brca1 modulates the autophosphorylation status of DNA-PKcs in S phase of the cell cycle</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>11487</fpage><lpage>11501</lpage><pub-id pub-id-type="doi">10.1093/nar/gku824</pub-id><pub-id pub-id-type="pmid">25223785</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DellâOste</surname><given-names>V</given-names></name><name><surname>Azzimonti</surname><given-names>B</given-names></name><name><surname>De Andrea</surname><given-names>M</given-names></name><name><surname>Mondini</surname><given-names>M</given-names></name><name><surname>Zavattaro</surname><given-names>E</given-names></name><name><surname>Leigheb</surname><given-names>G</given-names></name><name><surname>Weissenborn</surname><given-names>SJ</given-names></name><name><surname>Pfister</surname><given-names>H</given-names></name><name><surname>Michael</surname><given-names>KM</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name><name><surname>Amantea</surname><given-names>A</given-names></name><name><surname>Landolfo</surname><given-names>S</given-names></name><name><surname>Gariglio</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>High beta-HPV DNA loads and strong seroreactivity are present in epidermodysplasia verruciformis</article-title><source>The Journal of Investigative Dermatology</source><volume>129</volume><fpage>1026</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1038/jid.2008.317</pub-id><pub-id pub-id-type="pmid">18923444</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DePristo</surname><given-names>MA</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Poplin</surname><given-names>R</given-names></name><name><surname>Garimella</surname><given-names>KV</given-names></name><name><surname>Maguire</surname><given-names>JR</given-names></name><name><surname>Hartl</surname><given-names>C</given-names></name><name><surname>Philippakis</surname><given-names>AA</given-names></name><name><surname>del Angel</surname><given-names>G</given-names></name><name><surname>Rivas</surname><given-names>MA</given-names></name><name><surname>Hanna</surname><given-names>M</given-names></name><name><surname>McKenna</surname><given-names>A</given-names></name><name><surname>Fennell</surname><given-names>TJ</given-names></name><name><surname>Kernytsky</surname><given-names>AM</given-names></name><name><surname>Sivachenko</surname><given-names>AY</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A framework for variation discovery and genotyping using next-generation DNA sequencing data</article-title><source>Nature Genetics</source><volume>43</volume><fpage>491</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1038/ng.806</pub-id><pub-id pub-id-type="pmid">21478889</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deriano</surname><given-names>L</given-names></name><name><surname>Roth</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Modernizing the nonhomologous end-joining repertoire: alternative and classical NHEJ share the stage</article-title><source>Annual Review of Genetics</source><volume>47</volume><fpage>433</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1146/annurev-genet-110711-155540</pub-id><pub-id pub-id-type="pmid">24050180</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutto</surname><given-names>I</given-names></name><name><surname>Scalera</surname><given-names>C</given-names></name><name><surname>Prosperi</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CREBBP and p300 lysine acetyl transferases in the DNA damage response</article-title><source>Cellular and Molecular Life Sciences</source><volume>75</volume><fpage>1325</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1007/s00018-017-2717-4</pub-id><pub-id pub-id-type="pmid">29170789</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbakry</surname><given-names>A</given-names></name><name><surname>JuhÃ¡sz</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>KC</given-names></name><name><surname>LÃ¶brich</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Atrx and recq5 define distinct homologous recombination subpathways</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2010370118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2010370118</pub-id><pub-id pub-id-type="pmid">33431668</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gheit</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mucosal and cutaneous human papillomavirus infections and cancer biology</article-title><source>Frontiers in Oncology</source><volume>9</volume><elocation-id>355</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2019.00355</pub-id><pub-id pub-id-type="pmid">31134154</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>RH</given-names></name><name><surname>Smolik</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Cbp/P300 in cell growth, transformation, and development</article-title><source>Genes &amp; Development</source><volume>14</volume><fpage>1553</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1101/gad.14.13.1553</pub-id><pub-id pub-id-type="pmid">10887150</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howie</surname><given-names>HL</given-names></name><name><surname>Koop</surname><given-names>JI</given-names></name><name><surname>Weese</surname><given-names>J</given-names></name><name><surname>Robinson</surname><given-names>K</given-names></name><name><surname>Wipf</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>L</given-names></name><name><surname>Galloway</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Beta-HPV 5 and 8 E6 promote p300 degradation by blocking AKT/p300 association</article-title><source>PLOS Pathogens</source><volume>7</volume><elocation-id>e1002211</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1002211</pub-id><pub-id pub-id-type="pmid">21901101</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Bugbee</surname><given-names>T</given-names></name><name><surname>Gamez</surname><given-names>M</given-names></name><name><surname>Wallace</surname><given-names>NA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Beta human papillomavirus 8E6 attenuates non-homologous end joining by hindering DNA-PKcs activity</article-title><source>Cancers</source><volume>12</volume><elocation-id>2356</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12092356</pub-id><pub-id pub-id-type="pmid">32825402</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Bugbee</surname><given-names>T</given-names></name><name><surname>Dacus</surname><given-names>D</given-names></name><name><surname>Palinski</surname><given-names>R</given-names></name><name><surname>Wallace</surname><given-names>NA</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>Beta human papillomavirus 8 E6 allows colocalization of non-homologous end joining and homologous recombination repair factors</article-title><source>PLOS Pathogens</source><volume>18</volume><elocation-id>e1010275</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1010275</pub-id><pub-id pub-id-type="pmid">35148356</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Doerksen</surname><given-names>T</given-names></name><name><surname>Bugbee</surname><given-names>T</given-names></name><name><surname>Wallace</surname><given-names>NA</given-names></name><name><surname>Palinski</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Using next generation sequencing to identify mutations associated with repair of a CAS9-induced double strand break near the CD4 promoter</article-title><source>Journal of Visualized Experiments</source><volume>1</volume><elocation-id>62583</elocation-id><pub-id pub-id-type="doi">10.3791/62583</pub-id><pub-id pub-id-type="pmid">35435904</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Wallace</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2022">2022c</year><article-title>Beta HPV deregulates double-strand break repair</article-title><source>Viruses</source><volume>14</volume><elocation-id>948</elocation-id><pub-id pub-id-type="doi">10.3390/v14050948</pub-id><pub-id pub-id-type="pmid">35632690</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hufbauer</surname><given-names>M</given-names></name><name><surname>Cooke</surname><given-names>J</given-names></name><name><surname>van der Horst</surname><given-names>GTJ</given-names></name><name><surname>Pfister</surname><given-names>H</given-names></name><name><surname>Storey</surname><given-names>A</given-names></name><name><surname>AkgÃ¼l</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Human papillomavirus mediated inhibition of DNA damage sensing and repair drives skin carcinogenesis</article-title><source>Molecular Cancer</source><volume>14</volume><elocation-id>183</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-015-0453-7</pub-id><pub-id pub-id-type="pmid">26511842</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iliakis</surname><given-names>G</given-names></name><name><surname>Murmann</surname><given-names>T</given-names></name><name><surname>Soni</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Alternative end-joining repair pathways are the ultimate backup for abrogated classical non-homologous end-joining and homologous recombination repair: implications for the formation of chromosome translocations</article-title><source>Mutation Research. Genetic Toxicology and Environmental Mutagenesis</source><volume>793</volume><fpage>166</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.mrgentox.2015.07.001</pub-id><pub-id pub-id-type="pmid">26520387</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Crowe</surname><given-names>JL</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Nakajima</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>BJ</given-names></name><name><surname>Dubois</surname><given-names>RL</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Lan</surname><given-names>L</given-names></name><name><surname>Zha</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Differential phosphorylation of DNA-PKcs regulates the interplay between end-processing and end-ligation during nonhomologous end-joining</article-title><source>Molecular Cell</source><volume>58</volume><fpage>172</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.02.024</pub-id><pub-id pub-id-type="pmid">25818648</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>JuhÃ¡sz</surname><given-names>S</given-names></name><name><surname>Elbakry</surname><given-names>A</given-names></name><name><surname>Mathes</surname><given-names>A</given-names></name><name><surname>LÃ¶brich</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Atrx promotes DNA repair synthesis and sister chromatid exchange during homologous recombination</article-title><source>Molecular Cell</source><volume>71</volume><fpage>11</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.05.014</pub-id><pub-id pub-id-type="pmid">29937341</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>KÃ¶tter</surname><given-names>A</given-names></name><name><surname>Cornils</surname><given-names>K</given-names></name><name><surname>Borgmann</surname><given-names>K</given-names></name><name><surname>Dahm-Daphi</surname><given-names>J</given-names></name><name><surname>Petersen</surname><given-names>C</given-names></name><name><surname>Dikomey</surname><given-names>E</given-names></name><name><surname>Mansour</surname><given-names>WY</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Inhibition of PARP1-dependent end-joining contributes to olaparib-mediated radiosensitization in tumor cells</article-title><source>Molecular Oncology</source><volume>8</volume><fpage>1616</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2014.06.008</pub-id><pub-id pub-id-type="pmid">25028150</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kremsdorf</surname><given-names>D</given-names></name><name><surname>Jablonska</surname><given-names>S</given-names></name><name><surname>Favre</surname><given-names>M</given-names></name><name><surname>Orth</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Biochemical characterization of two types of human papillomaviruses associated with epidermodysplasia verruciformis</article-title><source>Journal of Virology</source><volume>43</volume><fpage>436</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1128/JVI.43.2.436-447.1982</pub-id><pub-id pub-id-type="pmid">6287026</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leeman</surname><given-names>JE</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Bell</surname><given-names>A</given-names></name><name><surname>Hussain</surname><given-names>SS</given-names></name><name><surname>Majumdar</surname><given-names>R</given-names></name><name><surname>Rong-Mullins</surname><given-names>X</given-names></name><name><surname>Blecua</surname><given-names>P</given-names></name><name><surname>Damerla</surname><given-names>R</given-names></name><name><surname>Narang</surname><given-names>H</given-names></name><name><surname>Ravindran</surname><given-names>PT</given-names></name><name><surname>Lee</surname><given-names>NY</given-names></name><name><surname>Riaz</surname><given-names>N</given-names></name><name><surname>Powell</surname><given-names>SN</given-names></name><name><surname>Higginson</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Human papillomavirus 16 promotes microhomology-mediated end-joining</article-title><source>PNAS</source><volume>116</volume><fpage>21573</fpage><lpage>21579</lpage><pub-id pub-id-type="doi">10.1073/pnas.1906120116</pub-id><pub-id pub-id-type="pmid">31591214</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Fast and accurate long-read alignment with burrows-wheeler transform</article-title><source>Bioinformatics</source><volume>26</volume><fpage>589</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp698</pub-id><pub-id pub-id-type="pmid">20080505</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Jones</surname><given-names>T</given-names></name><name><surname>Palomero</surname><given-names>L</given-names></name><name><surname>Pujana</surname><given-names>MA</given-names></name><name><surname>Martinez-Ruiz</surname><given-names>H</given-names></name><name><surname>Ha</surname><given-names>PK</given-names></name><name><surname>Murnane</surname><given-names>J</given-names></name><name><surname>Cuartas</surname><given-names>I</given-names></name><name><surname>Seoane</surname><given-names>J</given-names></name><name><surname>Baumann</surname><given-names>M</given-names></name><name><surname>Linge</surname><given-names>A</given-names></name><name><surname>Barcellos-Hoff</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Subjugation of TGFÎ² signaling by human papilloma virus in head and neck squamous cell carcinoma shifts DNA repair from homologous recombination to alternative end joining</article-title><source>Clinical Cancer Research</source><volume>24</volume><fpage>6001</fpage><lpage>6014</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-1346</pub-id><pub-id pub-id-type="pmid">30087144</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Palomero</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>J</given-names></name><name><surname>Guix</surname><given-names>I</given-names></name><name><surname>EspÃ­n</surname><given-names>R</given-names></name><name><surname>AytÃ©s</surname><given-names>A</given-names></name><name><surname>Mao</surname><given-names>J-H</given-names></name><name><surname>Paulovich</surname><given-names>AG</given-names></name><name><surname>Whiteaker</surname><given-names>JR</given-names></name><name><surname>Ivey</surname><given-names>RG</given-names></name><name><surname>Iliakis</surname><given-names>G</given-names></name><name><surname>Luo</surname><given-names>D</given-names></name><name><surname>Chalmers</surname><given-names>AJ</given-names></name><name><surname>Murnane</surname><given-names>J</given-names></name><name><surname>Pujana</surname><given-names>MA</given-names></name><name><surname>Barcellos-Hoff</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Loss of TGFÎ² signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types</article-title><source>Science Translational Medicine</source><volume>13</volume><elocation-id>eabc4465</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abc4465</pub-id><pub-id pub-id-type="pmid">33568520</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luedeman</surname><given-names>ME</given-names></name><name><surname>Stroik</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Luthman</surname><given-names>AJ</given-names></name><name><surname>Gupta</surname><given-names>GP</given-names></name><name><surname>Ramsden</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Poly (ADP) ribose polymerase promotes DNA polymerase theta-mediated end joining by activation of end resection</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>4547</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-32166-7</pub-id><pub-id pub-id-type="pmid">35927262</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>Z</given-names></name><name><surname>Bozzella</surname><given-names>M</given-names></name><name><surname>Seluanov</surname><given-names>A</given-names></name><name><surname>Gorbunova</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Comparison of nonhomologous end joining and homologous recombination in human cells</article-title><source>DNA Repair</source><volume>7</volume><fpage>1765</fpage><lpage>1771</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2008.06.018</pub-id><pub-id pub-id-type="pmid">18675941</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIntosh</surname><given-names>MT</given-names></name><name><surname>Koganti</surname><given-names>S</given-names></name><name><surname>Boatwright</surname><given-names>JL</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Spadaro</surname><given-names>SV</given-names></name><name><surname>Brantly</surname><given-names>AC</given-names></name><name><surname>Ayers</surname><given-names>JB</given-names></name><name><surname>Perez</surname><given-names>RD</given-names></name><name><surname>Burton</surname><given-names>EM</given-names></name><name><surname>Burgula</surname><given-names>S</given-names></name><name><surname>MacCarthy</surname><given-names>T</given-names></name><name><surname>Bhaduri-McIntosh</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Stat3 imparts BRCAness by impairing homologous recombination repair in Epstein-Barr virus-transformed B lymphocytes</article-title><source>PLOS Pathogens</source><volume>16</volume><elocation-id>e1008849</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008849</pub-id><pub-id pub-id-type="pmid">33002095</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murthy</surname><given-names>V</given-names></name><name><surname>Dacus</surname><given-names>D</given-names></name><name><surname>Gamez</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Wendel</surname><given-names>SO</given-names></name><name><surname>Snow</surname><given-names>J</given-names></name><name><surname>Kahn</surname><given-names>A</given-names></name><name><surname>Walterhouse</surname><given-names>SH</given-names></name><name><surname>Wallace</surname><given-names>NA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Characterizing DNA repair processes at transient and long-lasting double-strand DNA breaks by immunofluorescence microscopy</article-title><source>Journal of Visualized Experiments</source><volume>1</volume><elocation-id>57653</elocation-id><pub-id pub-id-type="doi">10.3791/57653</pub-id><pub-id pub-id-type="pmid">29939192</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neale</surname><given-names>RE</given-names></name><name><surname>Weissenborn</surname><given-names>S</given-names></name><name><surname>Abeni</surname><given-names>D</given-names></name><name><surname>Bavinck</surname><given-names>JNB</given-names></name><name><surname>Euvrard</surname><given-names>S</given-names></name><name><surname>Feltkamp</surname><given-names>MCW</given-names></name><name><surname>Green</surname><given-names>AC</given-names></name><name><surname>Harwood</surname><given-names>C</given-names></name><name><surname>de Koning</surname><given-names>M</given-names></name><name><surname>Naldi</surname><given-names>L</given-names></name><name><surname>Nindl</surname><given-names>I</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name><name><surname>Proby</surname><given-names>C</given-names></name><name><surname>Quint</surname><given-names>WG</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Wieland</surname><given-names>U</given-names></name><name><surname>Pfister</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Human papillomavirus load in eyebrow hair follicles and risk of cutaneous squamous cell carcinoma</article-title><source>Cancer Epidemiology, Biomarkers &amp; Prevention</source><volume>22</volume><fpage>719</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-12-0917-T</pub-id><pub-id pub-id-type="pmid">23396961</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orthwein</surname><given-names>A</given-names></name><name><surname>Noordermeer</surname><given-names>SM</given-names></name><name><surname>Wilson</surname><given-names>MD</given-names></name><name><surname>Landry</surname><given-names>S</given-names></name><name><surname>Enchev</surname><given-names>RI</given-names></name><name><surname>Sherker</surname><given-names>A</given-names></name><name><surname>Munro</surname><given-names>M</given-names></name><name><surname>Pinder</surname><given-names>J</given-names></name><name><surname>Salsman</surname><given-names>J</given-names></name><name><surname>Dellaire</surname><given-names>G</given-names></name><name><surname>Xia</surname><given-names>B</given-names></name><name><surname>Peter</surname><given-names>M</given-names></name><name><surname>Durocher</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A mechanism for the suppression of homologous recombination in G1 cells</article-title><source>Nature</source><volume>528</volume><fpage>422</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1038/nature16142</pub-id><pub-id pub-id-type="pmid">26649820</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pathania</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>J</given-names></name><name><surname>Hill</surname><given-names>SJ</given-names></name><name><surname>Scully</surname><given-names>R</given-names></name><name><surname>Adelmant</surname><given-names>GO</given-names></name><name><surname>Marto</surname><given-names>JA</given-names></name><name><surname>Feunteun</surname><given-names>J</given-names></name><name><surname>Livingston</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Brca1 is required for postreplication repair after UV-induced DNA damage</article-title><source>Molecular Cell</source><volume>44</volume><fpage>235</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2011.09.002</pub-id><pub-id pub-id-type="pmid">21963239</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patterson-Fortin</surname><given-names>J</given-names></name><name><surname>DâAndrea</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Exploiting the microhomology-mediated end-joining pathway in cancer therapy</article-title><source>Cancer Research</source><volume>80</volume><fpage>4593</fpage><lpage>4600</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-20-1672</pub-id><pub-id pub-id-type="pmid">32651257</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfister</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Chapter 8: human papillomavirus and skin cancer</article-title><source>JNCI Monographs</source><volume>2003</volume><fpage>52</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.jncimonographs.a003483</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>AJ</given-names></name><name><surname>Johnson</surname><given-names>RD</given-names></name><name><surname>Thompson</surname><given-names>LH</given-names></name><name><surname>Jasin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Xrcc3 promotes homology-directed repair of DNA damage in mammalian cells</article-title><source>Genes &amp; Development</source><volume>13</volume><fpage>2633</fpage><lpage>2638</lpage><pub-id pub-id-type="doi">10.1101/gad.13.20.2633</pub-id><pub-id pub-id-type="pmid">10541549</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapp</surname><given-names>A</given-names></name><name><surname>Greulich</surname><given-names>KO</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>After double-strand break induction by UV-A, homologous recombination and nonhomologous end joining cooperate at the same DSB if both systems are available</article-title><source>Journal of Cell Science</source><volume>117</volume><fpage>4935</fpage><lpage>4945</lpage><pub-id pub-id-type="doi">10.1242/jcs.01355</pub-id><pub-id pub-id-type="pmid">15367581</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogakou</surname><given-names>EP</given-names></name><name><surname>Pilch</surname><given-names>DR</given-names></name><name><surname>Orr</surname><given-names>AH</given-names></name><name><surname>Ivanova</surname><given-names>VS</given-names></name><name><surname>Bonner</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Dna double-stranded breaks induce histone H2AX phosphorylation on serine 139</article-title><source>The Journal of Biological Chemistry</source><volume>273</volume><fpage>5858</fpage><lpage>5868</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.10.5858</pub-id><pub-id pub-id-type="pmid">9488723</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rollison</surname><given-names>DE</given-names></name><name><surname>Viarisio</surname><given-names>D</given-names></name><name><surname>Amorrortu</surname><given-names>RP</given-names></name><name><surname>Gheit</surname><given-names>T</given-names></name><name><surname>Tommasino</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>An emerging issue in oncogenic virology: the role of beta human papillomavirus types in the development of cutaneous squamous cell carcinoma</article-title><source>Journal of Virology</source><volume>93</volume><elocation-id>e01003-18</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.01003-18</pub-id><pub-id pub-id-type="pmid">30700603</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname><given-names>A</given-names></name><name><surname>Conrad</surname><given-names>S</given-names></name><name><surname>Birraux</surname><given-names>J</given-names></name><name><surname>Geuting</surname><given-names>V</given-names></name><name><surname>Barton</surname><given-names>O</given-names></name><name><surname>Ismail</surname><given-names>A</given-names></name><name><surname>Kakarougkas</surname><given-names>A</given-names></name><name><surname>Meek</surname><given-names>K</given-names></name><name><surname>Taucher-Scholz</surname><given-names>G</given-names></name><name><surname>LÃ¶brich</surname><given-names>M</given-names></name><name><surname>Jeggo</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Factors determining DNA double-strand break repair pathway choice in G2 phase</article-title><source>The EMBO Journal</source><volume>30</volume><fpage>1079</fpage><lpage>1092</lpage><pub-id pub-id-type="doi">10.1038/emboj.2011.27</pub-id><pub-id pub-id-type="pmid">21317870</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sichero</surname><given-names>L</given-names></name><name><surname>Rollison</surname><given-names>DE</given-names></name><name><surname>Amorrortu</surname><given-names>RP</given-names></name><name><surname>Tommasino</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Beta human papillomavirus and associated diseases</article-title><source>Acta Cytologica</source><volume>63</volume><fpage>100</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1159/000492659</pub-id><pub-id pub-id-type="pmid">30673666</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simsek</surname><given-names>D</given-names></name><name><surname>Jasin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Alternative end-joining is suppressed by the canonical NHEJ component XRCC4-ligase IV during chromosomal translocation formation</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>17</volume><fpage>410</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1773</pub-id><pub-id pub-id-type="pmid">20208544</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snow</surname><given-names>JA</given-names></name><name><surname>Murthy</surname><given-names>V</given-names></name><name><surname>Dacus</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Wallace</surname><given-names>NA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Î²-HPV 8E6 attenuates ATM and ATR signaling in response to UV damage</article-title><source>Pathogens</source><volume>8</volume><elocation-id>267</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens8040267</pub-id><pub-id pub-id-type="pmid">31779191</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spriggs</surname><given-names>CC</given-names></name><name><surname>Laimins</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Human papillomavirus and the DNA damage response: exploiting host repair pathways for viral replication</article-title><source>Viruses</source><volume>9</volume><elocation-id>232</elocation-id><pub-id pub-id-type="doi">10.3390/v9080232</pub-id><pub-id pub-id-type="pmid">28820495</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tommasino</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hpv and skin carcinogenesis</article-title><source>Papillomavirus Research</source><volume>7</volume><fpage>129</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.pvr.2019.04.003</pub-id><pub-id pub-id-type="pmid">30953864</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Truong</surname><given-names>LN</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>LZ</given-names></name><name><surname>Hwang</surname><given-names>PYH</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Razavian</surname><given-names>N</given-names></name><name><surname>Berns</surname><given-names>MW</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Microhomology-mediated end joining and homologous recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells</article-title><source>PNAS</source><volume>110</volume><fpage>7720</fpage><lpage>7725</lpage><pub-id pub-id-type="doi">10.1073/pnas.1213431110</pub-id><pub-id pub-id-type="pmid">23610439</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>LJ</given-names></name><name><surname>Lopezcolorado</surname><given-names>FW</given-names></name><name><surname>Bhargava</surname><given-names>R</given-names></name><name><surname>Mendez-Dorantes</surname><given-names>C</given-names></name><name><surname>Jahanshir</surname><given-names>E</given-names></name><name><surname>Stark</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Rnf8 has both Ku-dependent and independent roles in chromosomal break repair</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>6032</fpage><lpage>6052</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa380</pub-id><pub-id pub-id-type="pmid">32427332</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukuda</surname><given-names>M</given-names></name><name><surname>Miyazaki</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dna fragmentation caused by an overdose of Zeocin</article-title><source>Journal of Bioscience and Bioengineering</source><volume>116</volume><fpage>644</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1016/j.jbiosc.2013.05.004</pub-id><pub-id pub-id-type="pmid">23727351</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viarisio</surname><given-names>D</given-names></name><name><surname>MÃ¼ller-Decker</surname><given-names>K</given-names></name><name><surname>Accardi</surname><given-names>R</given-names></name><name><surname>Robitaille</surname><given-names>A</given-names></name><name><surname>DÃ¼rst</surname><given-names>M</given-names></name><name><surname>Beer</surname><given-names>K</given-names></name><name><surname>Jansen</surname><given-names>L</given-names></name><name><surname>Flechtenmacher</surname><given-names>C</given-names></name><name><surname>Bozza</surname><given-names>M</given-names></name><name><surname>Harbottle</surname><given-names>R</given-names></name><name><surname>Voegele</surname><given-names>C</given-names></name><name><surname>Ardin</surname><given-names>M</given-names></name><name><surname>Zavadil</surname><given-names>J</given-names></name><name><surname>Caldeira</surname><given-names>S</given-names></name><name><surname>Gissmann</surname><given-names>L</given-names></name><name><surname>Tommasino</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Beta HPV38 oncoproteins act with a hit-and-run mechanism in ultraviolet radiation-induced skin carcinogenesis in mice</article-title><source>PLOS Pathogens</source><volume>14</volume><elocation-id>e1006783</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006783</pub-id><pub-id pub-id-type="pmid">29324843</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>NA</given-names></name><name><surname>Robinson</surname><given-names>K</given-names></name><name><surname>Howie</surname><given-names>HL</given-names></name><name><surname>Galloway</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Hpv 5 and 8 E6 abrogate ATR activity resulting in increased persistence of UVB induced DNA damage</article-title><source>PLOS Pathogens</source><volume>8</volume><elocation-id>e1002807</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1002807</pub-id><pub-id pub-id-type="pmid">22807682</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>NA</given-names></name><name><surname>Gasior</surname><given-names>SL</given-names></name><name><surname>Faber</surname><given-names>ZJ</given-names></name><name><surname>Howie</surname><given-names>HL</given-names></name><name><surname>Deininger</surname><given-names>PL</given-names></name><name><surname>Galloway</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Hpv 5 and 8 E6 expression reduces ATM protein levels and attenuates LINE-1 retrotransposition</article-title><source>Virology</source><volume>443</volume><fpage>69</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2013.04.022</pub-id><pub-id pub-id-type="pmid">23706308</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>NA</given-names></name><name><surname>Robinson</surname><given-names>K</given-names></name><name><surname>Howie</surname><given-names>HL</given-names></name><name><surname>Galloway</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Î²-HPV 5 and 8 E6 disrupt homology dependent double strand break repair by attenuating BRCA1 and BRCA2 expression and foci formation</article-title><source>PLOS Pathogens</source><volume>11</volume><elocation-id>e1004687</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004687</pub-id><pub-id pub-id-type="pmid">25803638</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Rosidi</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Iliakis</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Parp-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways</article-title><source>Nucleic Acids Research</source><volume>34</volume><fpage>6170</fpage><lpage>6182</lpage><pub-id pub-id-type="doi">10.1093/nar/gkl840</pub-id><pub-id pub-id-type="pmid">17088286</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JL</given-names></name><name><surname>Duboc</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Ochi</surname><given-names>T</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Tsutakawa</surname><given-names>SE</given-names></name><name><surname>Lees-Miller</surname><given-names>SP</given-names></name><name><surname>Nadal</surname><given-names>M</given-names></name><name><surname>Tainer</surname><given-names>JA</given-names></name><name><surname>Blundell</surname><given-names>TL</given-names></name><name><surname>Strick</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dissection of DNA double-strand-break repair using novel single-molecule forceps</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>25</volume><fpage>482</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1038/s41594-018-0065-1</pub-id><pub-id pub-id-type="pmid">29786079</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wendel</surname><given-names>SO</given-names></name><name><surname>Wallace</surname><given-names>NA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Loss of genome fidelity: beta hpvs and the DNA damage response</article-title><source>Frontiers in Microbiology</source><volume>8</volume><elocation-id>2250</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2017.02250</pub-id><pub-id pub-id-type="pmid">29187845</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81923.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Heyer</surname><given-names>Wolf-Dietrich</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05rrcem69</institution-id><institution>University of California, Davis</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.07.29.501983" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.07.29.501983"/></front-stub><body><p>This article reports useful data on how human papillomavirus 8E6 protein regulates DSB repair pathways in human cells. The data support the claim that 8E6 promotes alternative end-joining through binding and destabilizing the p300 acetyltransferase, showing the involvement of PARP-1-dependent alternative end-joining and to a lesser degree DNA Polymerase theta-dependent alternative end-joining.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81923.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Heyer</surname><given-names>Wolf-Dietrich</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05rrcem69</institution-id><institution>University of California, Davis</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Heyer</surname><given-names>Wolf-Dietrich</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05rrcem69</institution-id><institution>University of California, Davis</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.07.29.501983">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.07.29.501983v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Î human papillomavirus 8E6 promotes alternative end-joining&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Wolf-Dietrich Heyer as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Jessica Tyler as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Recommendations for the authors:</p><p>This study reports convincing data that in 8E6 expressing cells DSB repair is shifted towards alt-EJ at the expense of NHEJ and HR, following logically previous published studies with HPV16 and earlier work that 8E6 inhibits NHEJ and HR but does not preempt DSB repair. It is important to show experimentally, what might be considered evident, but the advance remains rather incremental. In addition, the study remains descriptive and offers little insight into the mechanisms involved other than it involves and binding (and inferred destruction) of p300. How p300 regulates DSB repair pathway choice remains unclear and is not further illuminated by this study. To add some novelty that goes beyond the HPV16 studies and closing an evident gap in the argument it to demonstrate an involvement of DNA polymerase theta to ascertain that the alt-EJ pathway involved is TMEJ. While most essential revisions require only text changes or clarifications, #4 is critical and will involve novel experimentation testing the involvement of DNA polymerase theta.</p><p>Essential revisions:</p><p>1) Abstract, line 24: There appear to be several alt-EJ pathways. Does this refer to TMEJ? If so, it seems now to be clear that TMEJ has a unique function and is not a backup pathway as evinced by the POLq KO phenotype and recent publications on POLq action in mitosis. See also lines 90 and 108.</p><p>2) Please address the following points either by text changes or a rebuttal:</p><p>Introduction:</p><p>Leeman et al. 2019 and Liu et al. 2018 and 2021 are precedents and should be in the introduction.</p><p>Lines 263-264:</p><p>The sentence is self-serving as Leeman et al. 2019 and Liu et al. 2018 are precedents.</p><p>Line 266:</p><p>Weaver et al., 2015 is incorrectly referenced. The paper reports that HPV+ HNSCC are sensitive to PARP inhibition but does not report a mutational signature or evidence of alt-EJ.</p><p>Lines 265-66:</p><p>The correlation of a mutational signature consistent with increased Alt-EJ across TCGA was reported by Liu et al. 2021.</p><p>Lines 267:</p><p>The statement that 8E6 causes a similar signature is a tautology.</p><p>Lines 269-73:</p><p>The statement that the ability to promote Alt-EJ seems to have evolved at least twice independently in the HPV family needs more clarification-Isn't E6 similar in both HPV16 and HPV8? And given that it is loss of HR/NHEJ that promotes the use of alt-EJ, the statement (line 273) that there is &quot;strong selective pressure for HPV (a non-lytic virus) to find a way to repair DSBs&quot; is not correct.</p><p>3) Primary and h-TERT immortalized human foreskin keratinocytes are not sufficiently described-is this one or multiple sources, at what passage were experiments conducted, was mycoplasma testing routine, how was cell identity verified? Similar questions pertain to U20S.</p><p>4) It seems critical to experimentally test an involvement of DNA polymerase theta (POLq) in the 8E6-induced alt-EJ events reported here. This does not require showing POLq dependence for each and every assay but available POLq KO cell lines or knockdown systems should test this point for some of the endpoints reported here.</p><p>This will also require an additional paragraph in the introduction and discussion to highlight the complexity of alt-EJ pathways to put TMEJ in context.</p><p>5) Can the authors explain the quite large differences in Alt-EJ activity between figures; e.g., in figure 1 the imbedded activity is 12.46% versus 22% in figure 2. Is this transfection efficiency? A note in the manuscript may be required to explain this.</p><p>6) The alt-EJ assay (Bhargava et al.) should be discussed in more detail and the relevant figure should show the nucleotide sequences involved. In particular, the involvement of the 4 nt microhomology should be discussed, as for this event the assay is significantly POLq-dependent (Figure 4 of Bhargava et al.). This becomes also important in the discussion of the genomic DNA sequencing data.</p><p>7) In a publication too recent for the author to include but relevant for the interpretation and discussion of their PARPi data, Luedeman et al. (2022 Nature Comm PMID: 35927262) showed a rather modest effect of PARP on TMEJ. In a revision, this publication should be included and discussed.</p><p>8) Figure 4AB. The results are not well described in the text. Isn't the key result that lesions (Î³ H2AX foci) are down in 8E6 expressing cells?</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;Î human papillomavirus 8E6 promotes alternative end-joining&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by Paivi Ojala (Senior Editor) and a Reviewing Editor.</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>Recommendations for the authors:</p><p>The authors addressed the concerns of the reviewers by adding the requested experiments testing the involvement of DNA polymerase theta and making the necessary text changes and adding clarifications.</p><p>The following changes are required before acceptance:</p><p>Figure 2 supplement 1A and C: Add some white space between the 2 blots to indicate that these are separate.</p><p>Please clarify and make sure that the loading controls (GAPDH) were run on the same gel from which the Cas9 signal was derived in Figure 2 supplement 1A and C.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81923.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Abstract, line 24: There appear to be several alt-EJ pathways. Does this refer to TMEJ? If so, it seems now to be clear that TMEJ has a unique function and is not a backup pathway as evinced by the POLq KO phenotype and recent publications on POLq action in mitosis. See also lines 90 and 108.</p></disp-quote><p>We thank the reviewers for this suggestion. The experiments suggested in essential revision 4 allowed us to determine that at least some of the DSB repair promoted by 8E6 requires POLÎ¸. However, 8E6 did not increase POLÎ¸ abundance. We have now changed the language in the abstract and have added a figure examining the dependence of DSB repair on POLÎ¸ activity in 8E6 expressing cells. Because these data did not show that all of the DSB repair in 8E6 expressing cells occurred in a POLÎ¸-dependent manner, we have chosen not to switch to the term TMEJ. We do not know that if our use of the term Alt-EJ includes all the mechanisms detectable by the reporter assays, including TMEJ. Please see abstract and discussion of the new figure 3.</p><disp-quote content-type="editor-comment"><p>2) Please address the following points either by text changes or a rebuttal:</p><p>Introduction:</p><p>Leeman et al. 2019 and Liu et al. 2018 and 2021 are precedents and should be in the introduction.</p></disp-quote><p>These references are now mentioned in the discussion to provide context to our discovery. We are open to moving them to the introduction if desired but preferred this approach for organizational reasons. See line 303-308.</p><disp-quote content-type="editor-comment"><p>Lines 263-264:</p><p>The sentence is self-serving as Leeman et al. 2019 and Liu et al. 2018 are precedents.</p></disp-quote><p>This line has been removed. See line 303-304.</p><disp-quote content-type="editor-comment"><p>Line 266:</p><p>Weaver et al., 2015 is incorrectly referenced. The paper reports that HPV+ HNSCC are sensitive to PARP inhibition but does not report a mutational signature or evidence of alt-EJ.</p></disp-quote><p>We have removed this reference.</p><disp-quote content-type="editor-comment"><p>Lines 265-66:</p><p>The correlation of a mutational signature consistent with increased Alt-EJ across TCGA was reported by Liu et al. 2021.</p></disp-quote><p>We now mention this fact. See line 303-308.</p><disp-quote content-type="editor-comment"><p>Lines 267:</p><p>The statement that 8E6 causes a similar signature is a tautology.</p></disp-quote><p>This has been fixed. See line 303-308.</p><disp-quote content-type="editor-comment"><p>Lines 269-73:</p><p>The statement that the ability to promote Alt-EJ seems to have evolved at least twice independently in the HPV family needs more clarification-Isn't E6 similar in both HPV16 and HPV8? And given that it is loss of HR/NHEJ that promotes the use of alt-EJ, the statement (line 273) that there is &quot;strong selective pressure for HPV (a non-lytic virus) to find a way to repair DSBs&quot; is not correct.</p></disp-quote><p>We respectfully disagree with this conclusion. There are similarities between the E6s from HPV8 and HPV 16. However, Leeman et al. demonstrated that HPV16 E7 promotes the use of Alt-EJ, while we show that HPV8 E6 promotes the pathway. Thus, in a member of one genus of HPV (Î²-papillomaviruses) the E6 protein evolved to promote Alt-EJ, while in another genus of HPV (Î±-papillomaviruses) the E7 protein evolved to promote Alt-EJ. We have modified our language to make this point clearer and to soften our claims as we acknowledge that we have no evolutionary evidence. Please see line 303-309.</p><disp-quote content-type="editor-comment"><p>3) Primary and h-TERT immortalized human foreskin keratinocytes are not sufficiently described-is this one or multiple sources, at what passage were experiments conducted, was mycoplasma testing routine, how was cell identity verified? Similar questions pertain to U20S.</p></disp-quote><p>Primary and hTERT-immortalized human foreskin keratinocytes (HFK) were derived from separate donors. All cell lines in this study underwent regular mycoplasma testing. HFK cell line identity was confirmed by growth in restrictive growth media. The identity of U2OS cells was confirmed based on the presence of the integrated DR-GFP cassette used to measure homologous recombination. They are the only cell line in our lab that contains this cassette. This information along with approximate passage numbers for HFK is now included in the resubmission as part of the methods section. We are unable to provide passage information for the U2OS cells as this information was not provided to the Ï when he acquired them as a post-doctoral fellow. Please see lines 322-335 and Key Resources Table.</p><disp-quote content-type="editor-comment"><p>4) It seems critical to experimentally test an involvement of DNA polymerase theta (POLq) in the 8E6-induced alt-EJ events reported here. This does not require showing POLq dependence for each and every assay but available POLq KO cell lines or knockdown systems should test this point for some of the endpoints reported here.</p><p>This will also require an additional paragraph in the introduction and discussion to highlight the complexity of alt-EJ pathways to put TMEJ in context.</p></disp-quote><p>We appreciate this suggestion from the reviewers and have taken a three-pronged approach to address it: (i) performing western blot analysis of Pol Theta to determine if 8E6 changed the abundance of the protein, (ii) determining if Pol Theta inhibition by small molecule specifically impeded DSB repair (microscopy of pH2AX) in 8E6 expressing HFKs, and (iii) determining if 8E6 made cells dependent on Pol Theta for survival. These data demonstrated that 8E6 promotes the use of TMEJ, but that it does not cause cells to become exclusively reliant on the pathway. The description of these results and the data itself can now be found in Figure 3 and lines 115-139. It is also discussed in lines 262-267. We should note that instead of using the cell lines suggested that we used HFKs and an inhibitor because they are more biologically relevant.</p><disp-quote content-type="editor-comment"><p>5) Can the authors explain the quite large differences in Alt-EJ activity between figures; e.g., in figure 1 the imbedded activity is 12.46% versus 22% in figure 2. Is this transfection efficiency? A note in the manuscript may be required to explain this.</p></disp-quote><p>The reviewers are correct. The differences in magnitude are the result of differences in transfection efficiency. This motivated us to correct for transfection efficiency during our initial analysis (Figure 1âfigure supplement 1, Figure 2âfigure supplement 1, and Figure 4âfigure supplement 1). Unfortunately, we did not mention this in our original submission. We now note how we accounted for differences in transfection efficiency. Please see line 100-102.</p><disp-quote content-type="editor-comment"><p>6) The alt-EJ assay (Bhargava et al.) should be discussed in more detail and the relevant figure should show the nucleotide sequences involved. In particular, the involvement of the 4 nt microhomology should be discussed, as for this event the assay is significantly POLq-dependent (Figure 4 of Bhargava et al.). This becomes also important in the discussion of the genomic DNA sequencing data.</p></disp-quote><p>We added the requested details for the Alt-EJ assay. Please see Figure1 legend and line 98.</p><disp-quote content-type="editor-comment"><p>7) In a publication too recent for the author to include but relevant for the interpretation and discussion of their PARPi data, Luedeman et al. (2022 Nature Comm PMID: 35927262) showed a rather modest effect of PARP on TMEJ. In a revision, this publication should be included and discussed.</p></disp-quote><p>We have added a discussion of the data described in Luedeman et al. and thank the reviewers for bringing this to our attention. Please see lines 116-118.</p><disp-quote content-type="editor-comment"><p>8) Figure 4AB. The results are not well described in the text. Isn't the key result that lesions (Î³ H2AX foci) are down in 8E6 expressing cells?</p></disp-quote><p>We have made the requested changes. Please see lines 159-162.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>Recommendations for the authors:</p><p>The authors addressed the concerns of the reviewers by adding the requested experiments testing the involvement of DNA polymerase theta and making the necessary text changes and adding clarifications.</p><p>The following changes are required before acceptance:</p><p>Figure 2 supplement 1A and C: Add some white space between the 2 blots to indicate that these are separate.</p></disp-quote><p>Thank you for this suggestion. We added space between blots for all figures. We also added outlines for blots to make it clear.</p><disp-quote content-type="editor-comment"><p>Please clarify and make sure that the loading controls (GAPDH) were run on the same gel from which the Cas9 signal was derived in Figure 2 supplement 1A and C.</p></disp-quote><p>We confirm that all loading controls (GAPDH) were run on the same gel from which the CAS9 signals were derived. This is correct for all figures.</p></body></sub-article></article>